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Immune-induced activation of the hypothalamic-pituitary-adrenal (HPA) axis elevates 
glucocorticoids, anti-inflammatory hormones, promoting the effective resolution of 
inflammation. Psychological stress can modulate this anti-inflammatory mechanism, but the 
mechanisms underlying this modulation remain largely unknown. The immune-induced HPA 
axis activation is, in large part, mediated by prostaglandin E2 (PGE2), an inflammatory 
mediator. In the brain, PGE2 attenuates GABAergic synaptic transmission onto corticotropin-
releasing hormone (CRH) neurons in the paraventricular nucleus of the hypothalamus (PVN) 
that act as the apex of the HPA axis. The removal of GABA-mediated inhibition (i.e. 
disinhibition) excites CRH neurons and, consequently, activates the HPA axis. Here, we 
examined the modulatory effects of psychological stress on this PGE2-mediated synaptic 
mechanism for HPA axis activation. To this end, we used whole-cell patch clamp 
electrophysiology to record GABAergic synaptic transmission onto PVN-CRH neurons as 
changes in the amplitude of evoked inhibitory post-synaptic current (eIPSCs). We contrasted 
findings in acute brain slices from mice that have been stressed by restraint (psychological 
stress) with those of naïve (non-stressed) mice. We first confirmed that, in slices from naïve 
mice, PGE2 potently depressed GABAergic synaptic transmission to PVN-CRH neurons. On 
the other hand, in slices from stressed mice, PGE2 had heterogeneous effects, potentiating some 
synapses in addition to depressing others. Using receptor subtype-specific agonists and 
antagonists, we showed that the EP3 subtype of the PGE2 receptor mediated the synaptic 
depression by inhibiting the release of GABA from the pre-synaptic terminals in naïve slices. 
On the other hand, the EP2 and EP4 receptors mediated the potentiation of GABA release from 
the pre-synaptic terminals. Acute stress did not alter these mechanisms for bidirectional 
synaptic plasticity. By contrast, a blockade of EP1 receptor mimicked the effects of stress, 
shifting the balance of depression and potentiation toward potentiation. We conclude that EP1 
receptor suppresses EP2 and EP4-mediated pre-synaptic potentiation (thus making EP3-
mediated depression dominant) and that psychological stress blocks this EP1-mediated 
mechanism. We propose that psychological stress modulates the interplay between different 
subtypes of EP receptors to ultimately contribute to altering the immune-induced activation of 
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Threats to homeostasis, either real or anticipated, trigger a wide array of highly coordinated 
behavioral and physiological changes to defend or re-establish homeostasis (Bains, 
Wamsteeker Cusulin, & Inoue, 2015; Johnson, Kamilaris, Chrousos, & Gold, 1992) – this 
response is collectively termed the “stress response” (Chrousos, 2009). A major regulator of 
stress response is the activation of the hypothalamic-pituitary-adrenal (HPA) axis, resulting 
in an elevation of glucocorticoids (GCs) in circulation. GCs act throughout the periphery and 
in the brain to mediate various changes associated with the stress response, including the 
feedback inhibition of the HPA axis. In addition to this rapid response, an important aspect of 
HPA axis activation is that the response is highly plastic and undergoes long-term changes in 
its function. In other words, prior stress exposures change the responsiveness of the HPA axis 
to future stressors. This plasticity enables organisms to fine-tune their response to their 
dynamic environment. However, such flexibility also makes the system susceptible to 
dysregulation, resulting in maladaptive changes. For example, excessive stress has been 
linked hypo- and hyper-sensitivity of the HPA axis (Chrousos & Kino, 2007; Faravelli et al., 
2012; Ogawa et al., 1994). The mechanisms underlying the flexibility of the HPA axis are 
complex and remain largely unknown. The general goal of my M.Sc. thesis is to investigate 
neural mechanisms that contribute to the plasticity of the HPA axis. Specifically, this thesis 
examines the neural mechanisms involved in the activation of the HPA axis in response to 
inflammation (one type of stressor) and how these mechanisms are altered by prior stress 
exposure. To this end, this M.Sc. thesis focused on one type of synapses terminating on a 
population of neurons in the hypothalamus that initiates the HPA axis and examined 1) how 
these synapses respond to inflammatory signals, and 2) how they change their responsiveness 
to an inflammatory signal following stress exposure. 
1.2 The stress response 
The stress response is the collective set of responses of the body to stimuli that disrupt or 




changes, including heightened alertness, suppression of appetite, sleep, and reproductive 
drive, as well as increased heart rate, respiratory rate, blood pressure, and metabolism 
(Chrousos, 2009; Griffin, 1990; Smith & Vale, 2006). The stress response is primarily 
adaptive, however, when in excess, the stress response can have detrimental consequences. 
Chronic stress has been correlated with physiological conditions like Type II diabetes, 
obesity, and hypertension (Chrousos, 2009; Elenkov & Chrousos, 1999;) as well as to 
psychiatric disorders such as panic attacks, anxiety, and depression (Chrousos, 2000; 
Contarino et al., 1999; Hammen, Kim, Eberhart, & Brennan, 2009; Johnson et al., 1992; 
Pervanidou & Chrousos, 2010; Yehuda, Giller, Southwick, Lowy, & Mason, 1991). Given its 
connection to pervasive diseases and mental disorders, it is important to understand how the 
brain regulates the stress response. 
1.3 The HPA axis 
1.3.1 Composition of HPA axis 
The main neuroendocrine mediator of the stress response is the HPA axis. The HPA axis is 
composed of a hormonal cascade involving the hypothalamus, the anterior pituitary and the 
adrenal cortex (Figure 1-1). Corticotropin-releasing hormone (CRH) neurons in the 
paraventricular nucleus of the hypothalamus (PVN) form the apex of the HPA axis. The cell 
bodies of these neurons are clustered in the medial parvocellular subdivision of the PVN. 
These neurons send projections to the median eminence, a part of the hypothalamus that is 
integral to the hypophyseal portal system. The median eminence lacks the blood-brain-
barrier. Thus, CRH released from axonal projections in the median eminence enters the 
portal circulation to reach the anterior pituitary. At the anterior pituitary, CRH binds to the 
CRH type 1 receptor (CRHR1) on corticotroph cells. CRHR1 stimulation triggers the 
transcription of the pro-opiomelanocortin (POMC) gene; a precursor polypeptide that will be 
enzymatically cleaved into adrenocorticotropic hormone (ACTH) and other peptides like β-
endorphins. ACTH will then be released from the anterior pituitary into the systemic 
bloodstream (Stalla, Stalla, Loeffler, von Werder, & Müller, 1987). ACTH binds to 
melanocortin type 2 receptors (MC2-R), a Gαs coupled receptor and stimulates the synthesis 
and release of GCs from the zona fasciculate of the adrenal cortex (Herman et al., 2016; 




the body via the general circulation and induce an array of psychophysiological changes 
associated with the stress response. GCs also exert negative feedback regulation over the 






























Figure 1-1: Schematic of the HPA axis.
Corticotropin-releasing hormone (CRH) is secreted from neurons of the paraventricular 
nucleus of the hypothalamus (PVN). In turn, CRH  cause the anterior pituitary gland to 
secrete adrenocorticotropic hormone (ACTH). ACTH causes the adrenal cortex to secrete 
glucocorticoid (GC) for negative feedback regulation of the HPA axis.  
  
CRH 








1.3.2 Actions of GCs 
 
GCs are a class of steroid hormones. They are essential for normal life as they regulate or 
support physiological processes in the cardiovascular, metabolic, immune and other systems. 
For example, GCs cause increased cardiac output, energy metabolism through glucose 
mobilization, increased cerebral blood flow, vasoconstriction and immune modulation 
(Sapolsky, Romero, & Munck, 2000; Smith & Vale, 2006). 
GCs act via two receptors: mineralocorticoid receptor (MR) and glucocorticoid receptor 
(GR) (de Kloet, Joëls, & Holsboer, 2005). MRs are expressed in many tissue/cell types of the 
body, including the kidneys, heart, brown adipose tissue, and sweat glands. By contrast, GRs 
are ubiquitous. In the CNS, MRs expression is predominantly restricted to the lateral septum 
and hippocampus, while GR expression is ubiquitous across brain areas and cell types, 
including stress-related brain regions like the hippocampus, the prefrontal cortex, the 
amygdala and the PVN (Herman et al., 2003; Reul & de Kloet, 1985). Like other steroid 
hormone receptor family members, MRs and GRs are ligand-dependent transcription factors 
that act in the nucleus. Non-liganded MRs/GRs are found in the cytoplasm as large oligomers 
with heat shock protein (HSP)s. When GC binds MR or GR, it activates the receptor by 
releasing the HSP. The activated GR or MR binds hormone response element (HRE)s, a 
receptor-specific DNA-binding site associated with hormone-regulated genes, that alter 
transcription (Guyre, 1998). Corticosterone (CORT), the major GC in rodents, is bound with 
six- to ten-fold greater affinity by MRs (Kd = 0.5 nM) than GRs (Kd = 2.5-5 nM) (Reul & de 
Kloet, 1985). In other words, MRs are occupied by low levels of GCs. MRs were 80% 
occupied by a 1 mg/100 g (subcutaneous) body weight dose of CORT. On the other hand, 
50% occupation of GRs required doses of 50-100 mg/100 g body weight (Reul & de Kloet, 
1985). Given its occupation at the baseline and relative lack of further occupation by stress-
induced increases in GC, it has been proposed that MR signaling plays a role in preparing the 
body for the initiation of the stress response (when the concentration is low) (de Kloet et al., 
2005; Finsterwald & Alberini, 2014). The lower affinity of GRs allows for differential 
binding at the basalth(low GC) and stress-induced conditions (higher concentrations of GCs). 




With relevance to the plasticity of stress response, GRs are implicated in the formation and 
consolidation of aversive memory by modulating plasticity mechanisms in brain areas such 
as the hippocampus and amygdala (Finsterwald & Alberini, 2014; Lupien, Maheu, Tu, 
Fiocco, & Schramek, 2007). The memory of stress, in turn, modifies future stress response 
(de Kloet et al., 2005; Lupien et al., 2007; Yuen et al., 2009). GC activation of GRs also 
mediates negative feedback regulation of the HPA axis by suppressing production of CRH 
and ACTH in the PVN and the anterior pituitary, respectively (Smith & Vale, 2006; Tasker 
& Herman, 2011). Thus, GRs serve a vital role in terminating the HPA axis stress response 
(Herman, McKlveen, Solomon, Carvalho-Netto, & Myers, 2012). GRs can mediate the 
strength of negative feedback to influence the magnitude of HPA axis activity (de Kloet & 
Reul, 1987; van Haarst, Oitzl, & de Kloet, 1997). 
1.4 Regulating activation of HPA axis 
The activity of the HPA axis is influenced by a wide range of external and internal signals, 
which are integrated by the neural circuits, ultimately converging on the PVN. While there 
are many different modalities of stress, they are broadly categorized as physiological or 
psychological. It is generally believed that different modalities of stressors recruit distinct 
neuronal circuits reaching to the PVN to deploy a common stress response, the activation of 
the HPA axis (Figure 1-2) (Bains et al., 2015).  
1.4.1 Physiological stress 
Physiological stress is a real disturbance to homeostasis (Dayas, Buller, Crane, Xu, & Day, 
2001). Physiological stressors include inflammation, hypoxia, pain, starvation, 
hypoglycemia, and hyper-/hypo-thermia (Colaianna et al., 2013; Price, 2000). A major 
neuronal pathway for physiological stressors to activate the HPA axis is relayed by the brain 
stem nuclei. Specifically, catecholaminergic (adrenergic and noradrenergic) cell groups in the 
nucleus of solitary tract and the ventrolateral medulla send direct, monosynaptic projections 
to the PVN (Herman & Cullinan, 1997; Ulrich-Lai & Herman, 2009). The activation of these 
adrenergic and noradrenergic inputs are essential for the activation of the HPA axis following 
various physiological, but not psychological, stress (Buller, Xu, Dayas, & Day, 2001; Li, 




1.4.2 Psychological stress 
Psychological stress is a perceived threat to homeostasis that is not associated with physical 
disturbances (Dickerson & Kemeny, 2004). Psychological stressors include predator odor, 
novel environment, social isolation and social conflict among conspecifics (Pruessner et al., 
2010). Despite the lack of physical changes in bodily parameters, psychological stress 
likewise activates the HPA axis. 
Psychological stress recruits cortico-limbic structures including the prefrontal cortex, 
hippocampus, and amygdala to signal through hypothalamic (e.g. dorsomedial hypothalamus 
(DMH)) and peri-hypothalamic nuclei (e.g. bed nucleus of stria terminalis (BNST)) to the 
PVN (Flak, Solomon, Jankord, Krause, & Herman, 2012; Ulrich-Lai & Herman, 2009). It 
was proposed that this signaling pathway is “multi-layered” meaning that it has intercepting 
structures between the brain areas involved such that it has “processing anticipatory” (Bains 
et al., 2015). This implies that previous stress information can be stored, in the forms of 
synaptic and neural plasticity after stress (Bliss & Collingridge, 1993; Foy, Stanton, Levine, 
& Thompson, 1987; Schwabe & Wolf, 2012). Stored information from previous stress 
exposure could modify the subsequent stress response, leading to sensitization or 

























Figure 1-2: Neuronal circuitry involved in signaling physiological and psychological 
stressors to activate the HPA axis. 
Physiological stress (blue) acts through the brainstem nuclei of the ventromedial medulla 
(VM) and the nucleus of the solitary tract (NTS) that send direct catecholaminergic, 
monosynaptic projections (solid black arrows) to the paraventricular nucleus of the 
hypothalamus (PVN). This neuronal pathway is necessary for the activation of the 
hypothalamic-pituitary-adrenal (HPA) axis in response to systemic inflammation, a 
prototypical physiological stressor (Herman & Cullinan, 1997; Ulrich-Lai & Herman, 2009). 
Psychological stress (red) has “multi-layered” processing involving the corticolimbic 
structures (prefrontal cortex [PFC], amygdala, hippocampus) and hypothalamic (dorsomedial 
hypothalamus [DMH]) and peri-hypothalamic structures (bed nucleus of stria terminalis 
[BNST]) that signal to the PVN. This pathway is believed to play major roles in the 
activation the HPA axis in response to restraint stress, a psychological stressor (Flak et al., 




1.4.3 Converging physiological and psychological stress 
modalities 
As discussed above, different types of stressors converge to activate the HPA axis. This 
convergence suggests the possibility for interactions between different modalities of stress 
(Bains et al., 2015). For example, it has been shown that tail shock stress 1 day prior to 
systemic inflammation sensitized the activation of the HPA by the inflammation (Johnson et 
al., 2002). By contrast, it has also been shown that 7 days of twice daily 10-minute restraints 
attenuated HPA axis activation by an inflammation trigger (Gadek-Michalska, Spyrka, & 
Bugajski, 2005). However, it remains largely unexplored how one type of stressor modifies 
the subsequent response to a different stressor, particularly stressors of different modalities. 
This thesis investigates the interactions between two modalities of stress: a physiological 
stressor and a psychological stressor. I will identify how the synaptic mechanisms for 
inflammation (physiological stressor)-induced HPA axis activation can be modulated by a 
prior exposure to immobilization stress (psychological stressor). 
1.5 Anti-inflammatory regulation by GCs 
Inflammation is a response primarily mediated by the immune system, which protects our 
body from injury and infection (Barton, 2008; Nathan, 2002). The inflammatory response 
involves coordinated immunovascular responses that deliver immune agents (Newton & 
Dixit, 2012) to eliminate the infection and repair the injury (Barton, 2008). While generally 
pro-survival, unregulated (or excessive) inflammation can have adverse consequences. 
Unregulated inflammation can include prolonged (chronic) or exaggerated inflammation 
implicated in various disease conditions including atherosclerosis, rheumatoid arthritis, and 
sepsis (Barton, 2008; Elenkov & Chrousos, 1999; Hench, Kendall, Slocumb, & Polley, 
1949). Therefore, inflammation needs to be tightly regulated. One of the signals regulating 
inflammation is GCs. In addition to their stress-related actions, GCs are potent anti-
inflammatory mediators. Thus, immune-induced activation of the HPA axis provides a 
critical negative feedback regulation for the resolution of inflammatory response.  
GCs can modulate gene expression for immuno-suppressive and anti-inflammatory actions in 
many ways. GCs, via GR binding, block the transcription factor activator protein-1 (AP-1) 




factor nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and prevent it 
from binding to DNA to initiate transcription of pro-inflammatory cytokines. GCs binding to 
GRs also increases the synthesis of NFκB inhibitor alpha (IκBα). GRs also negatively 
regulate mRNA stability of various pro-inflammatory cytokines (Guyre, 1998; Ruzek, 
Pearce, Miller, & Biron, 1999). 
1.6 Peripheral inflammation mechanism of signaling to affect 
CNS 
Peripheral inflammation initiates when cells of the immune system such as tissue 
macrophages and monocytes recognize inflammatory stimuli, such as the bacterial endotoxin, 
lipopolysaccharide (LPS), via surface-expressed pattern recognition receptors (Aderem & 
Ulevitch, 2000; Alexander & Rietschel, 2001; Medzhitov & Janeway, 2000). Activated 
innate immune cells then secrete cytokines and other inflammatory mediators that spread the 
inflammatory signals to the body and/or further recruits other immune cells to the site of 
inflammation (adaptive immune response) (Galic, Riazi, & Pittman, 2012). Inflammation 
originating peripherally can be sensed by the CNS by multiple pathways including the vagal 
afferents, circumventricular organs (which lacks the blood-brain-barrier [BBB]), and through 
the BBB (Blatteis, 2007; Ransohoff, Kivisäkk, & Kidd, 2003). 
In response to the afferent inflammatory signals, the CNS initiates the an overlapping 
inflammatory response in the CNS, including synthesis of pro-inflammatory cytokines (Layé, 
Parnet, Goujon, & Dantzer, 1994; Pyter, Pineros, Galang, McClintock, & Prendergast, 2009; 
Quan, Stern, Whiteside, & Herkenham, 1999; Riazi et al., 2008; Rothwell, Luheshi, & 
Toulmond, 1996; Turrin et al., 2001). One of the major downstream mediators of this 
cytokine cascade is prostaglandin E2 (PGE2) (Ricciotti & FitzGerald, 2011), which is 
synthesized by endothelial and perivascular cells (Morimoto, Murakami, Nakamori, Sakata, 
& Watanabe, 1989; Rivier & Vale, 1991). This thesis will focus on PGE2 as it is the final 
signaling molecule for the activation of the HPA axis via CRH neurons.  
1.7 PGE2 and the neuroendocrine stress response 
PGE2 is a highly studied mediator initiating the immune-induced activation of the HPA axis 




made by oxidizing 20 carbon polyunsaturated fatty acids derived from phospholipids 
comprising the cellular membrane. Specifically, PGE2 is synthesized from the 20 carbon 
polyunsaturated fatty acid of arachidonic acid. Arachidonic acid is cleaved from membrane 
phospholipids by phospholipase A2. Cyclooxygenase (COX) enzymes convert arachidonic 
acid into PGH2. There are two subtypes of the COX enzyme: COX-1 (constitutive) and 
COX-2 (inducible). COX-1 is the dominant source of PGs for housekeeping functions, such 
as gastric epithelial cytoprotection and homeostasis, while COX-2 serves to synthesize PGs 
triggered by stimuli, such as in response to growth factors or in proliferative diseases like 
cancer; both COX can contribute to PG release during inflammation (Dubois et al., 1998). 
PGH2 is converted into many different PGs by specific synthases (Kalinski, 2012; Narumiya, 
Sugimoto, & Ushikubi, 1999). PGE2 is synthesized from PGH2 by prostaglandin E synthase. 
Several prostaglandin E synthases have been identified, but to date, microsomal 
prostaglandin E synthase-1 (mPGES-1) emerges as the key enzyme for the creation of PGE2 
in the brain during inflammation (Elander et al., 2009).  
1.8 PGE2 receptors 
PGE2 can act by binding to at least four different G-protein-coupled receptors (GPCR) 
termed E prostanoid (EP) receptor: EP1, EP2, EP3, and EP4 (Furuyashiki & Narumiya, 2009; 
Sugimoto & Narumiya, 2007). The four PGE2 receptors have different G-protein α subunits. 
EP1 receptor signals via Gαq and increases intracellular calcium (Ca
2+) level which can 
influence vesicle release (Narumiya et al., 1999; Woodward, Jones, & Narumiya, 2011). EP2 
and EP4 receptors are each linked with Gαs which activates adenylate cyclase (AC) to 
increase the levels of cyclic adenosine monophosphate (cAMP) in the cells. cAMP 
subsequently allows activation of protein kinase A (PKA) that acts on cAMP response 
elements binding proteins (CREB) in order to exert its effects (Narumiya et al., 1999). EP3 
receptors are primarily coupled with Gαi/o in the PVN, which decreases the level cAMP (in a 
manner opposite that of Gαs). Interestingly, EP3 receptor, through Gβγ, has been shown to 
mobilize intracellular Ca2+ (Hatae, Sugimoto, & Ichikawa, 2002; Zhang et al., 2011; 






Figure 1-3: PGE2 receptors subtypes include: EP1, EP2, EP3, EP4.  
All four types of EP receptors are G-protein coupled receptors (GPCR). The Gαi/o-coupled 
EP3 receptor suppresses adenylate cyclase (AC) and decrease the creation of cyclic adenosine 
monophosphate (cAMP). cAMP typically activates protein kinase A (PKA) to act on cAMP 
response binding elements (CREB) (Hatae, Sugimoto, & Ichikawa, 2002; Zhang et al., 2011). 
By contrast, Gαs-coupled EP2 and EP4 receptors activate AC to increase cAMP and thus act 
on CREB (Narumiya et al., 1999). Gαq-coupled EP1 receptor increases intracellular calcium 
(Ca2+) which affects vesicle release and activates protein kinase C (PKC) which regulates EP 
receptors (Narumiya et al., 1999; Woodward, Jones, & Narumiya, 2011; Furuyashiki & 




The EP receptors are distributed widely throughout the body (Figure 1-3). For example, in 
rodents EP1 receptor is located in the papillary collecting ducts of the kidney, lungs, stomach, 
and thalamus, while in humans its location is restricted mast cells, pulmonary veins, 
keratinocytes, myometrium, and colon smooth muscle (Narumiya et al., 1999; Sugimoto & 
Narumiya, 2007). This thesis focuses on the relevance of the EP receptors to the HPA axis 
input, so it is important to elaborate on the presence of these receptors at and around the 
PVN. EP1 mRNA expression has been shown in the PVN using in situ hybridization (Oka et 
al., 2000). On the other hand, the PVN neurons do not express mRNA for EP3 (Zhang & 
Rivest, 1999). Other studies showed that EP3 receptor protein is present in GABA axon 
terminals on PVN neurons as demonstrated by immunohistochemistry in rat (Nakamura et 
al., 2000) and supported by in situ hybridization identifying EP3 mRNA expression in nuclei 
that send projections to the PVN (Ek, Arias, Sawchenko, & Ericsson-Dahlstrand, 2000). EP4 
receptor mRNA has been localized to the PVN (Zhang & Rivest, 1999, 2000). The existence 
of EP1, EP3, and EP4 receptors in PVN neurons or inputs support the findings that these 
receptors might be involved in modulating the HPA axis response to inflammation. A clear 





1.9 PGE2 in inflammation 
PGE2 is one of the most studied inflammatory mediators that activate the HPA axis. 
Numerous studies showed that systemic administration of LPS or pro-inflammatory 
cytokines, such as IL-1β and TNFα, induce COX-2 expression in the brain vasculature 
(Breder & Saper, 1996; Cao, Matsumura, Yamagata, & Watanabe, 1996; Quan, Whiteside, & 
Herkenham, 1998). Given that LPS and IL-1β were applied to the periphery, these data also 
led to the view that circulating afferent inflammatory signals are transduced into PGE2 at the 
cerebral vasculature (García-Bueno, Serrats, & Sawchenko, 2009). In this view, due to its 
small size and lipophilic properties, PGE2 diffuses into the brain to mediate the signaling 
cascade in the CNS that ultimately activates the HPA axis (Schiltz & Sawchenko, 2002, 
2003). In line with this idea, microinjection of exogenous PGE2 directly into the rat 
hypothalamus led to increased levels of the ACTH in the plasma (Katsuura, Arimura, Koves, 
& Gottschall, 1990; Morimoto et al., 1989), further clarifying that it is PGE2 acting in 
hypothalamus to activate the HPA axis. 
The importance of PGE2 in inflammation-induced HPA axis activation is further supported 
by pharmacological and genetic studies targeting PGE2 synthesis and signaling. 
Pharmacological inhibition of COX through application of indomethacin blocks the increase 
in ACTH and CORT concentration induced by IL-1β (Parsadaniantz et al., 2000) or by LPS 
(Matsuoka et al., 2003; Narumiya & Furuyashiki, 2011). Furthermore, mPGES-1 knockout 
mice show a blunted elevation of ACTH and CORT release after systemic LPS (Elander et 
al., 2009). HPA axis activation by systemic LPS has been shown to be completely abolished 
in mice lacking either EP1 or EP3 receptor (Furuyashiki & Narumiya, 2009; Matsuoka et al., 
2003).  
The neuronal mechanisms whereby PGE2 activates the HPA axis have only recently been 
fully explored. PGE2 acts on the GABA synapses on the PVN-CRH neuron (Ferri & 
Ferguson, 2003). So consequently, this thesis will next elaborate on the PVN, its CRH 





1.10 The PVN 
The PVN is the apex of the HPA axis, which is a structure that houses the synapses of focus 
for this thesis. The PVN is a nucleus in the hypothalamus located bilaterally adjacent to the 
dorsal tip of the third ventricle (Figure 1-4). In addition to neuroendocrine neurons that 
release CRH, the PVN contain several other types of neuroendocrine neurons that regulate 
metabolism, reproduction and osmotic balance, as well as non-neuroendocrine neurons that 
control the autonomic nervous system. Thus, the PVN is widely regarded as the center for the 
neuroendocrine and autonomic control (Swanson, Sawchenko, Rivier, & Vale, 1983). 
1.10.1 Characterization of neuronal subtypes of the PVN 
The PVN is composed of a diverse set of cell types corresponding to the diverse 
physiological roles of the nucleus. These neuron types have been classified by their 
morphological (i.e. size of their cell bodies), molecular (i.e. types of neuropeptide expressed) 
(Biag et al., 2012; Herman et al., 2003; Liposits, 1993; Swanson et al., 1983; Ulrich-Lai & 
Herman, 2009), anatomical (i.e. localization in the PVN subdivisions and their projection 
targets) (Swanson & Kuypers, 1980), and electrophysiological properties (i.e. spiking 
threshold) (Tasker & Dudek, 1991). The PVN also contains pre-autonomic neurons, which 
are non-neuroendocrine neurons that send projections to the brainstem and spinal cord to 
control the sympathetic tone (e.g. increase heart rate and blood pressure, regulate appetite) 
(Stern, 2001; Swanson & Sawchenko, 1983). In addition to these projection neurons (i.e. 
neuroendocrine and pre-autonomic neurons), the PVN contains a small population of 
interneurons. Recent studies have shown this monosynaptic connectivity using viral tracing 
and optogenetic circuit mapping (Jiang, Rajamanickam, & Justice, 2018). Yet, the local 
targets of these neurons and their physiological functions remains largely unknown. Since the 
different types of neurons can be classified by their distinct electrophysiological properties, a 
“fingerprint” can be used to distinguish the subtype during patch-clamp electrophysiology 
experiments (Luther, Halmos, & Tasker, 2000; Tasker & Dudek, 1991); this involves 
observing the characteristic response of different neurons to a current clamp protocol of 10 
pA stepwise depolarization (Figure 1-5 A). The three types of neurons present within the 




1.10.1.1 Magnocellular neurons 
Magnocellular neurons (MNC) are a group of neuroendocrine neurons that are characterized 
by relatively large cell body size (diameter of ~ 20-30 μm in rats) and possessing two to three 
sparsely branched primary dendrites oriented bidirectionally (Tasker & Dudek, 1991). MNCs 
are present in the anterior, medial and posterior PVN (Swanson & Sawchenko, 1983). MNCs 
project their axons to the posterior pituitary where hormones are stored and released directly 
into the blood-stream (Benarroch, 2005; Tasker & Dudek, 1991). MNCs synthesize oxytocin 
(OXY) (Hashimoto, Matsuura, & Ueta, 2014) and arginine vasopressin (AVP) (Berghorn, 
Knapp, Hoffman, & Sherman, 1995; Dohanics, Hoffman, & Verbalis, 1996; Renaud & 
Bourquet, 1991). OXY promotes suckling-induced milk ejection (Cunningham & 
Sawchenko, 1991), uterine contractions during labour (Blanks & Thornton, 2003), the stress 
response (Jezova, Skultetyova, Tokarev, Bakos, & Vigas, 1995; Piekut, Pretel, & Applegate, 
1996; Wotjak et al., 1998), and regulates body fluid volume (Leng, Brown, & Russell, 1999). 
AVP, also known as antidiuretic hormone (ADH), plays a major role in regulating the blood 
osmolality and volume (and thus electrolyte homeostasis) in response to dehydration and 
hypovolemia (Leng et al., 1999). During dehydration and hypovolemia, AVP acts on its 
receptors expressed in the distal or collecting tubules of the kidney to promote fluid retention 
by increasing water reabsorption and reducing urination (Aguilera & Rabadan-Diehl, 2000). 
Electrophysiologically, MNCs exhibit a pronounced delay to the first action potential with a 
transient outward rectification (Figure 1-5 B) in response to depolarizing current injection 
(Tasker & Dudek, 1991). This delay to first action potential is mediated by A-type voltage-
gated potassium channels, as is evidenced by their sensitivity to 4-aminopyridine (a selective 
blocker of members of Kv1 (Shaker) family of voltage-activated K+ channels) (Luther et al., 
2000). 
1.10.1.2 Neuroendocrine parvocellular neurons 
Parvocellular neurons are further classified into two neuronal subtypes based on their 
projection targets: neuroendocrine parvocellular neurons (PNCs) and pre-autonomic 
parvocellular neurons (PAs). PNCs are characterized by relatively small cell body size 
(diameter of ~ 10-25 μm in rats) and more branched dendrites in a bidirectional orientation 




& Sawchenko, 1983). PNCs send projections to the median eminence (Stern, 2015). PNCs 
synthesize and secrete anterior pituitary hormones including CRH, thyrotropin-releasing 
hormones (TRH), and somatostatin (SS) (also known as growth hormone-inhibiting hormone 
(GHIH)) (Ceccatelli, Villar, Goldstein, & Hökfelt, 1989; Pammer, Fodor, & Palkovits, 1988; 
Stern, 2015). CRH, as described in section 1.3.1, serves as the start of the HPA axis signaling 
to the anterior pituitary (Herman et al., 2003; Smith & Vale, 2006; Swanson et al., 1983). 
TRH initiates the hypothalamic–pituitary–thyroid axis (Lechan & Fekete, 2006; Luther & 
Tasker, 2000; Tasker & Dudek, 1991; Vale, Spiess, Rivier, & Rivier, 1981). GHIHs are best 
characterized for their actions in inhibiting growth hormone secretion (Olias et al., 2004), but 
also regulate the endocrine system, affect neurotransmission, cell proliferation, and inhibit 
the release of insulin and glucagon (Unger, Dobbs, and Orci, 1978). PNCs, in contrast to 
MNCs and PAs, are characterized by the absence of the prominent A-type K+ conductance 
and absence of the low-threshold T-type Ca2+ conductance (Figure 1-5 D) (Luther et al., 
2002). 
1.10.1.3 Pre-autonomic parvocellular neurons 
PA neurons are characterized by relatively small cell body size (diameter of ~ 11-25 μm in 
rats) and radially oriented, multipolar dendritic arbors (Tasker & Dudek, 1991). PAs are 
present in the dorsal and ventral PVN (Luther et al., 2002; Swanson & Sawchenko, 1983) 
and send projections to the brainstem, specifically the caudal medulla, and spinal cord 
autonomic control centers to regulate the autonomic functions (Luther et al., 2002; Stern, 
2001). Some PA neurons express neuropeptides that are found in neuro-endocrine neurons 
including CRH, OXY and AVP which act as neurotransmitters at the projection targets 
(Kalsbeek et al., 2010; Müller et al., 2000). For example, OXY neurons that regulate gastric 
reflexes; AVP neurons that are involved in regulating blood pressure, temperature, and 
brown fat thermogenesis; and CRH neurons, which are involved in the autonomic response to 
stress. PAs exhibit a short burst of large action potentials firing at a low threshold (Figure 1-
5 C) in response to depolarizing current injection (Luther et al., 2002). Given that the low-
threshold potentials persisted in tetrodotoxin (TTX) but were blocked by solutions containing 





Figure 1-4:The distribution of different types of neurons in the PVN. 
The PVN is composed of heterogeneous populations of neurons, including: corticotropin-
releasing hormone (CRH) neurons, thyrotropin-releasing hormone (TRH) neurons, growth 
hormone-inhibiting hormone (GHIH), tyrosine hydroxylase (TH) neurons, vasopressin 
(VAS), oxytocin (OXY), and growth  hormone-releasing  hormone (GRH) neurons. Adapted 






Figure 1-5: Electrophysiological properties of PVN neurons.
(A) Current clamp protocol for electrophysiological fingerprinting of PVN neurons. (B) 
Magnocellular neurons (MNC) exhibit a delay to the first action potential (arrow) due to A-
type K+ channel activation. (C) Parvocellular neuroendocrine neurons (PNC) lack the delay 
or low-threshold spike. (D) Parvocellular pre-autonomic neurons (PA) have a low-threshold 





1.11 GABA-mediated synaptic transmission on CRH neurons 
PVN-CRH neurons receive many GABAergic inputs. Specifically, electron microscopy 
imaging has identified that approximately half of the all synaptic terminals (46.2%) in the 
medial parvocellular PVN, which contains CRH neurons, are GABAergic (Miklós & Kovács, 
2002). This thesis will explore GABA function as it relates to the PVN-CRH neuron. 
1.11.1 GABA is an inhibitory neurotransmitter 
GABA, previously known as Factor Ι, was first identified for its action of inhibiting the 
formation of a stretch receptor neuron impulse in crayfish (Elliott & Flow, 1956). GABA is 
the major inhibitory neurotransmitter of the mammalian nervous system (Watanabe, 
Maemura, Kanbara, Tamayama, & Hayasaki, 2002). A large portion, approximately one 
sixth of all synapses, use GABA (Sheikh, Martin, & Martin, 1999; Somogyi, Tamás, Lujan, 
& Buhl, 1998). GABA is synthesized from L-glutamic acid by the enzyme glutamic acid 
decarboxylase (GAD). In mammals, GAD comes in two isoforms: GAD65 and GAD67, which 
have different tissue and subcellular distributions and functions (Kaufman, Houser, & Tobin, 
1991; Sheikh et al., 1999). Vesicular GABA transporter (VGAT) loads GABA into synaptic 
vesicles. Synaptic vesicle exocytosis is caused by fusion machinery activated by elevated 
levels of intracellular Ca2+ in synaptic terminals. Specifically, Ca2+-dependent 
synaptotagmins activate soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein 
receptor (SNARE)s to cause vesicle docking and fusion with the membrane. Ca2+ may be 
elevated in the pre-synaptic terminal due to an action potential, which causes voltage-gated 
Ca2+ channels to open and transiently increase the local Ca2+ concentration at the pre-
synaptic active zone (Südhof, 2012). Vesicle exocytosis causes the release of 
neurotransmitter into the synaptic cleft where transmitter may diffuse to receptors. GABA 
transporter (GAT) clears GABA neurotransmitter from the synaptic cleft in order to prevent 
further action (Scimemi, 2014). Once re-uptaken, GABA is metabolized into succinic acid by 





1.11.2 GABA receptors 
As described previously, GABA exerts its neurotransmission actions through receptors. The 
two classes of GABA receptor are: GABAA and GABAB, which differ in their 
pharmacological, electrophysiological and biochemical properties (Olsen & DeLorey, 1999). 
GABAA receptors are the main GABA receptor involved in fast synaptic transmission, so are 
the focus of this thesis. GABAA receptors are present in the CNS, including the PVN-CRH 
neurons as demonstrated by dual hybridization histochemistry (Cullinan, Ziegler, & Herman, 
2008). GABAA receptor is a hetero-pentameric transmembrane protein that is composed of 
subunits: α1-6, β1-3, γ1-3, δ, ε, θ, π, or ρ1-3 (Luscher, Fuchs, & Kilpatrick, 2011; Olsen & 
DeLorey, 1999), where different subunits combinations provide different functions (Olsen & 
Sieghart, 2009). GABAA receptors are ionotropic receptors, also known as ligand-gated ion 
channels, which selectively conduct chloride (Cl-). GABAA receptors allow Cl
- to flow across 
the membrane and down its electrochemical gradient. In adult neurons, the low intracellular 
Cl- compared to extracellular Cl- means GABAA receptors conduct influx of Cl
- at the resting 
membrane potential (i.e. -70 mV) which causes hyperpolarization of the post-synaptic 
membrane (Olsen & DeLorey, 1999; Wu & Sun, 2015). Cl- will flow out of the cell if the 
internal voltage is less than resting potential (i.e. -60 mV), and Cl- will flow in if it is more 
than resting potential (i.e. -75 mV), hyperpolarizing the membrane, resulting in an increase in 
the firing threshold and thus a reduction in the probability of action potential initiation, 
causing neuronal inhibition. Increased Cl- permeability can depolarize a neuron under some 
conditions of high intracellular Cl-, such as during development, which can instead excite the 
neuron (Owens, Boyce, Davis, & Kriegstein, 1996).  
GABAB receptors are found in the central nervous system and autonomic peripheral nervous 
system. GABAB receptors are metabotropic receptors, also known as G-protein coupled 
receptors, which are linked via a G-protein to potassium (K+) channels (Kaupmann et al., 
1998). GABAB receptors allow the flow of K
+ across the membrane at more hyperpolarized 
potentials, since the reversal potential of the GABAB-mediated inhibitory post-synaptic 





1.11.3 Inhibition of GABA disinhibits PVN-CRH neurons to 
activate the HPA axis 
GABA-mediated inhibition tonically acts on PVN-CRH neuron excitability and as a 
consequence constrains HPA axis activity (Cullinan et al., 2008; Makara & Stark, 1974). 
Microinjection of the competitive GABAA antagonist, bicuculline, into rat PVN induced a 
robust induction of c-Fos, an immediate early gene that informs a recent history of neural 
activity, in medial parvocellular PVN (Cole & Sawchenko, 2002). This activation of PVN 
neurons suggests their removal from tonic GABA-mediated inhibition. Another study by 
Hewitt et al. reported that bicuculline microinjection into the PVN increased the circulating 
corticosteroids, indicating that the release from the GABA-mediated inhibition leads to HPA 
axis activation (Hewitt, Wamsteeker, Kurz, & Bains, 2009). Additionally, by using cell-
attached recordings, this study showed bath application of bicuculline increased the spike 
activity of PNCs, suggesting that GABA typically inhibits their spiking (Hewitt et al., 2009).  
The PVN neurons receive this tonic GABA-mediated inhibition originating from many brain 
regions. Retrograde tracing and immunohistochemistry have identified the anterior 
perifornical area (a region of the bed nucleus of stria terminalis), peri supra-optic area, 
anterior hypothalamic, and dorsomedial hypothalamic nucleus as major origins of GABA 
projections to the PVN (Cullinan et al., 2008; Roland & Sawchenko, 1993; Ulrich-Lai & 
Herman, 2009). 
While there is strong evidence, as described in section 1.9, that PGE2 plays a key role in the 
activation of the HPA axis in response to inflammation (Morimoto et al., 1989; Rivier & 
Vale, 1991), it was not until recently that the literature explored how this effect may be 
achieved. PGE2 application during ex vivo electrophysiology patch clamp recording 
increased the spike frequency of PNCs neurons, suggesting that PGE2 can excite putative 
CRH neurons by locally acting at the PVN in slice preparation (Ferri & Ferguson, 2003; 
Ferri, Yuill, & Ferguson, 2005). Application of the GABAA antagonist, bicuculline, into the 
PVN mimicked PGE2-mediated excitation of the PNCs (Ferri et al., 2005). Given the known 
tonic inhibition of PVN-CRH neurons, one possible mechanism suggested in the literature 
whereby PGE2 could excite CRH neurons is to remove the GABA inhibition. These 




activates HPA axis (Ferri & Ferguson, 2003; Ferri et al., 2005). Our group recently further 
examined this mechanism and revealed that PGE2 acts on pre-synaptic EP3 receptors to 
depress the synaptic release of GABA onto PVN-CRH neurons (Khazaeipool, Wiederman, & 
Inoue, 2018). 
1.12 Rationale, hypothesis, aims 
1.12.1 Rationale 
The identification of a synaptic mechanism for inflammation-induced (i.e. PGE2-mediated) 
activation of PVN-CRH neurons paved a way to investigate the potential neuronal mechanisms 
for the integration of different stress information. That is, a number of in vivo studies have 
shown that prior stress exposure causes lasting changes in the regulatory mechanisms of the 
HPA axis, leading to hypo- and hyper-sensitivity of the neuroendocrine response to future 
stressors (Chrousos & Kino, 2007; Faravelli et al., 2012; Ogawa et al., 1994). For example, 
Johnston et al., demonstrated that 1, 4, and 10 days after a series of inescapable tail shocks 
(average intertrial interval = 60 s), the CORT and ACTH response of male rats to systemic 
LPS administration (10 μg/kg, intraperitoneal injection) significantly increased (Johnson et al., 
2002). Thus, this study demonstrated that exposure to one type of stressor, tail shock, can 
sensitize the ACTH and CORT response to subsequent HPA activation by a different stressor 
(inflammatory stress). On the other hand, a separate study found that 7 days of twice-a-day 10 
min restraint stress prior to LPS-induced inflammation, attenuated the typical rise of in plasma 
ACTH and CORT levels compared to control non-restrained male rats (Gadek-Michalska et 
al., 2005). These studies indicate that, different types and paradigms of stress exposure can 
bidirectionally change the responsiveness of the HPA axis to inflammatory stress. Building 
upon our recent finding that GABAergic synapses onto PVN-CRH neurons are the target of 
PGE2 (a key mediator of inflammatory stress), in this thesis we examined if and how prior 
exposure to a different type of stressor (restraint stress) alter the responsiveness of these GABA 
synapses to PGE2. Our use of restraint stress as the psychological stressor for this thesis most 
closely resembles the modality of stress employed by Gadek-Michelska et al. (2005); so our 
predictions align with their observation of an impairment of the inflammation-induced HPA 





Prior acute restraint stress impairs the synaptic mechanisms for PGE2-induced CRH neuron 
disinhibition. 
1.12.3 Aims 
To test the hypothesis, my thesis has three aims: 
Aim 1: To establish a mouse model to study the effects of PGE2 on GABA synapses onto 
PVN-CRH neurons.  
Previous studies by us and others that identified the actions of PGEs on GABAergic synapses 
in the PVN used rats. The development of CRH-reporter mouse line (Cusulin, Füzesi, Watts, 
& Bains, 2013) now allows us to visually identify CRH neurons for ex vivo patch clamp 
electrophysiology experiments. This is a major advancement in the field, as prior rat studies 
that form the basis of the rationale of this study (section 1.11.3) relied on the 
electrophysiological characteristics of PNC neurons that include not only CRH but other 
types of neuroendocrine neurons.  
Prior stress exposure may alter the electrophysiological characteristics of PVN neurons 
(Bittar et al., 2019; Senst, 2014), which could potentially introduce a sampling bias to 
previous studies on the effects of stress on the PGE2 actions in rats. Thus, I will first replicate 
the effects of PGE2 on GABAergic synapses onto PVN-CRH neurons in stress-naïve mice. 
Aim 2: To examine the impact of prior psychological stress on PGE2-mediated 
attenuation of GABA synapse. 
I will next explore the impact of psychological stress on the effects of PGE2 on GABAergic 






Aim 3: To examine synaptic mechanisms through which prior psychological stress alters 
the PGE2-induced depression of GABA synapses on CRH neurons.  
The effects of PGE2 on GABAergic synaptic transmission on CRH neurons of the PVN have 
previously been identified as EP3-dependent (Khazaeipool et al., 2018). I will examine if 
prior exposure to stress alters the EP3-mediated PGE2 action on GABA transmission on 
PVN-CRH neurons. I will also examine if prior exposure to stress alters the functions of the 
other EP receptors (EP1, EP2, and EP4) to change the overall effects of PGE2 on GABAergic 






Figure 1-6: Schematic diagram identifying the hypothesized synaptic mechanism of 
PGE2-induced activation of the HPA axis and its change after acute restraint stress.
(A) In naïve conditions, PGE2 activates the CRH neurons by depressing inhibitory GABA 
synaptic transmission via pre-synaptic EP3 receptor. (B) After acute restraint stress, the 






2 Materials and Methods 
2.1 Animal handling 
All the experiments involving the use of animals were approved by the institutional care and 
use committee of the University of Western Ontario in accordance with the guideline of the 
Canadian Counsel on Animal Care. Experiments were performed using male adult (7-16 
weeks old) CRH-reporter mice that express tdTomato red fluorescent protein in CRH 
neurons (Cusulin et al., 2013). These CRH reporter mice are on a C57BL/6 background and 
bred by crossing a homozygous CRH-IRES-Cre driver (Jackson Laboratories, stock #: 
012704) and a homozygous Cre-dependent ROSA26-tdTomato reporter (Jackson 
Laboratories, stock #: 007914) according to previous publications (Cusulin et al., 2013; 
Salter, Sunstrum, Matovic, & Inoue, 2018) in the University of Western Ontario animal 
facility. Animals were bred in a breeding facility in the campus and transferred to a housing 
room at least 5 days prior to experimentation. The animals were kept in a 12 h/12 h light–
dark cycle (light on at 7:00 AM). Food and water were provided ad libitum. Mice were 
housed in cages of 2 – 4 littermates. Mice were provided with a small, tinted, plastic shelter 
for environmental enrichment.  
Every effort was made to prevent causing any unnecessary distress to the animals including 
minimizing handling. For the acute restraint stress experiments, mice were immobilized for 1 
hour within a well-ventilated Falcon® 50 mL high-clarity polypropylene conical centrifuge 
tube (Fischer Scientific, cat #: 1495949A). A small hole was cut into the cap of the Falcon 
tube to allow the tail to protrude. A plunger was used to adjust the size of the tube to 
accommodate differently sized mice in appropriate restraint (Figure 2-1). Acute restraint was 
performed during the light phase, for 1 hour, between 9:00 AM and 12:00 PM. Immediately 
after the end of immobilization stress, animals were deeply anesthetized with isoflurane for 
decapitation and brain extraction. Animals not receiving acute restraint stress were 






Figure 2-1:7 Cartoon schematic of a mouse in restraint stress. 
The mouse is sufficiently restrained in the Falcon® 50 mL high-clarity polypropylene conical 




2.2 Slice preparation and maintenance 
The brain was quickly removed and immersed into ice-cold slicing solution containing (in 
mM: NaCl 87, KCl 2.5, NaHCO3 25, CaCl2·2H2O 0.5, MgCl2·6H2O 7, NaH2PO4 1.25, 
glucose [C6H12O6] 25, and sucrose [C12H22O11] 75, osmolality = 315 - 320 mOsm) saturated 
with 95% O2, 5% CO2. Coronal hypothalamic slices (250 μm) were cut using a vibratome 
(VT1200s, Leica Biosystems). Slices containing the PVN were identified based on their 
macroscopic features (location posterior to fornix and anterior to hippocampus) and trimmed 
and bisected to isolate individual PVN. Then, the trimmed PVN slices were placed into a 
slice chamber containing artificial cerebrospinal fluid (aCSF) made of (in mM: NaCl 126, 
KCl 2.5, NaHCO3 26, CaCl2·2H2O 2.5, MgCl2·6H2O 1.5, NaH2PO4·H2O 1.25, glucose 10, 
osmolality = 295 - 300 mOsm) saturated with 95% O2, 5% CO2. The slice chamber 
containing the brain slices was maintained at 35°C in a water bath incubator (Lauda, E100 
Ecoline Staredition) for 30 - 40 min. Afterwards, the chamber was removed from the 
incubator and held at room temperature (20 - 25°C) for 15 mins before use of the PVN slices. 
The chamber was maintained at room temperature for storage of slices until use for the 
remainder of the experiment.  
Before recording, the slice was transferred to the recording chamber and acclimatized for 15 
mins to the temperature and any drugs present in the aCSF (section 2.4). For example, this 
acclimatized slices to the presence of the AMPA kainate receptor antagonist, 6,7-
dinitroquinoxaline-2,3-dione (DNQX; 10 μM, Tocris Bioscience), which was constantly 
perfused to isolate GABAA receptors-mediated inhibitory post-synaptic current (IPSC)s. 
Throughout recording, the slice was constantly perfused with aCSF saturated with 95% O2, 
5% CO2 at a flow rate of 1-2 mL per min, which was warmed to 30°C using an in-line heater 
with a feedback sensor (Scientifica). After being transferred to the recording chamber, the 
acute brain slices of PVN were placed under the 40X objective (Scientifica manipulator) of 
an infrared differential interference contrast (light) microscope (Scientifica, serial #: 461016). 
A DAGE-MTI IR-1000 camera projected the microscope image onto a screen (Insignia). 
CRH neurons were identified by their fluorescence under green light (560–520 nm) emitted 
from a CoolLED pE-300. Healthy CRH neurons with intact and distinct membranes as was 




electrophysiology. All equipment including the microscope, recording chamber, and patch 
micromanipulators were stabilized using a CleanBench airtable (TMC, Gimbal Piston, 
Ametek). 
2.3 Electrophysiology 
2.3.1 Electrochemical gradients drive potential change across 
the membrane  
Electrophysiological measures record the current caused by the movement of ions. 
Membranes are relatively impermeable to ions. Ions can, however, move through open 
channels with their concentration gradient, or may be pumped through active transporters 
against their concentration gradient. Current (I) and voltage (V) are related by a factor of 
resistance (R) of the material conducting the ions through Ohm’s law:  
V = IR 
Voltage is the difference in electric potential energy between two positions. Thus, there can 
be a potential difference across a cell membrane, which separates ions (electrical potential). 
The Nernst equation is used to calculate the potential of an ion across a membrane that 
opposes net diffusion of an ion. The magnitude of the Nernst potential is determined by the 
ratio of the concentrations of that ion on the in and outside of the membrane; the greater this 
ratio the greater the tendency for the ion to diffuse in one direction and therefore the greater 









E is the membrane potential in volts (V),  
T is the temperature in Kelvin (K), 
R is the ideal gas constant (8.314459848 JK−1mol−1), 
F is Faraday's constant (96485.3328959 Cmol−1). 




[M]out is the extracellular concentration of that ion in moles (mol), 
[M]in is the intracellular concentration of that ion in moles (mol) 
The Nernst equation is derived from the Goldman equation under the assumption that the 
membrane is in thermodynamic equilibrium (no net flux of ions). The Goldman equation 

























 Pion is the permeability an ion (ms−1), thus accounting for flux 
The resting membrane potential (Vrest) is the potential of a membrane at rest when it is “at 
rest” (not actively undergoing an action potential). The electrochemical gradients made by 
ion pumps establishes the Vrest. To calculate the Vrest we use the concentration of these ions 
in the intracellular and extracellular space and their permeability; this gives us a Vrest for 
neurons of -68 mV primarily contributed to by the leakage of K+ out of the cell. The 
physiological and experimental concentration of the relevant ions contributing to the Nernst 





Table 2-1: Relevant ion concentrations in the extracellular and intracellular fluids.  
Ion concentrations are listed for the physiological and experimental (aCSF and internal) 
solutions. Adapted from (Bradbury & Davson, 1965; Contreras, Shoshani, Flores-
Maldonado, Lázaro, & Cereijido, 1999; Delpire & Staley, 2014; Khazaeipool et al., 2018). 
Equilibrium potentials were calculated based on our experimental aCSF and internal 
gradients. 
Ion 
Extracellular (mM) Intracellular (mM) Equilibrium 
potential (mV) Physiological aCSF Physiological Internal 
Na+ 130 – 150 153.25 10 15.4 +58 
K+ 3 – 9  2.5 140 132 -101 






The increased intracellular concentration of Cl- (in mM: physiological = 4, internal = 12) 
helps to drive the stronger inward current for recording. Inward and outward current is one 
way during voltage clamp to describe the direction of the flow of ions (Yamamoto, Fukami, 
& Washio, 1981). Inward ionic current is the flow of cations (positive charge) entering the 
cell. In relation to GABA, this is reversed, since GABAA receptors primarily conduct 
negative ions (i.e. Cl-). When recording eIPSCs of GABA on CRH neurons, I hold the 
membrane potential of the post-synaptic cell at -80 mV, which is below the equilibrium 
potential of GABAA receptors (calculated from the ion concentration in our aCSF and 
internal), and therefore observe inward ionic current, which is the flow of anions (negative 
charge) exiting the cell.  
2.3.2 Whole cell patch clamp: pipettes, internal and aCSF 
Borsosiliacate glass microelectrode (2-5 MΩ) were pulled using a micropipette puller 
(Flaming/Brown, model P1000, Sutter Instrument, CA, USA) and filled with internal 
solution consisted of (in mM: K-gluconate 116, KCl 8, Na-gluconate 12, K2-EGTA 1, 
HEPES 10, MgCl2 2, K2ATP 4, and Na3GTP 0.3) adjusted for pH (pH = 7.2 - 7.4) and 
osmolarity (osmolality = 283 - 289 mOsm).  
Once the pipette was in the aCSF under the microscope, the shape and taper were inspected, 
and then positive pressure was applied via tubing and maintained by closing a three-way 
value; positive pressure helped to clear debris from the pipette’s path when navigating the 
slice. A micromanipulator (Scientifica) was used to descend the pipette to target CRH 
neurons in the PVN that were identified by the expression of Tdtomato. When positive 
pressure was released, the neuron adhered to the electrode and formed a gigaseal (cell-
attached configuration). To get to whole-cell configuration for recording, the cell membrane 
was ruptured with brief suction.  
Access resistance (Ra), membrane resistance (Rm) and capacitance of the membrane (Cm) 
were examined at least every 5 min during recordings using a Membrane Test function in a 
data acquisition software (Clampex 10.7, Molecular devices). The Membrane Test applies a 
continuous square wave voltage, then fits an exponential to the responding current to 
calculate that Cm = 
Qt
ΔV




steady-state response (Q1) plus the correction factor (Q2) and ΔV is found via the steady-state 
equation where ΔI = 
ΔV
Ra+Rm
 (“Membrane Test Algorithms”, 2010). Recordings were 
discarded if it exceeded 20 MΩ or changed more than 20% from that of the baseline. 
Recordings were terminated if the Rm went below 500 MΩ. 
For current-clamp (IC) recordings, the baseline membrane potential of CRH neuron was 
adjusted by injecting a constant current of (0- -30pA) to achieve a voltage of approximately -
80 mV. CRH neurons were “fingerprinted” to check their type (magnocellular, parvocellular, 
pre-autonomic) using an IC protocol of 15 steps lasting 5 seconds each, beginning at -20 pA 
and increasing step-wise by 10 pA each time. Recordings were discarded if they were found 
to be magnocellular or pre-autonomic. Recordings were discarded if the resting membrane 
potential was more depolarized than -42 mV.  
For all voltage-clamp experiments, CRH neurons were held at -80 mV. A second 
borsosiliacate glass microelectrode (stimulating electrode) was filled with aCSF and placed 
ventromedial to the post-synaptic neuron to evoke IPSCs using a simulator (S88 Stimulator; 
duration = ~1.1 ms, Volts = 5 - 10 V). Specifically, for all experiments, I evoked a pair of 
IPSCs using two stimuli separated by 50 ms (0.2 Hz). The stimulating electrode was moved 
until it evoked a strong (minimum = 20 pA, average = 50 pA, and consistently firing) first 
evoked IPSC (eIPSC). Once the eIPSC stabilized, I recorded a baseline while flowing normal 
aCSF (-5 – 0 min, “baseline”), bath applied the drug for the experiment (0 – 5 min, “drug”), 
and then washed the drug out with aCSF (5 – 15 min, “post-drug”). 
2.4 Drugs 
This study used various agonists and antagonists for EP receptors. The names of all the drugs 
used is listed with their function in Table 2-2. All drugs were obtained from Cayman 
Chemical (Michigan, USA). The drugs were prepared into aliquots using the solvent listed in 
Table 2-2. Aliquots were stored at -20°C until the day of the experiment. As required for the 
experiments, aliquots of the drugs were diluted to the appropriate concentration (Table 2-2) 
in aCSF. The maximum concentration of the solvents (ethanol or dimethylsulfoxide 




was chosen based on its dose-response curves or use ex vivo, or if unavailable based on its 





Table 2-2: Drug information. 
The name, function, and catalogue number of all used drugs are listed. The binding 
efficiency of the drug is described by the dissociation constant (Ki), which is like the affinity 
constant of the enzyme and inhibitor complex, half maximal inhibitory concentration (IC50), 
the concentration that reduces operation of the target by 50%, or half maximal effective 
concentration (EC50), the concentration that increases operation of the target by 50%. The 
Cheng-Prussoff equation allows conversion of IC50 values to a more universal Ki for direct 






 if [S] is the substrate concentration and Km is 
Michaelis constant. The binding value and ex vivo literature were used to select the 
concentration of drug used in this thesis. Drugs were aliquoted in solvent to a concentration 
under saturation level. Aliquots were diluted in aCSF to the final concentration. 








PGE2 14010 Ki = 1-10 nM depending on 







Iloprost 18215 Ki = 11 nM (Abramovitz et al., 
2000) 




CP 544,326 22945 IC50 = 15 nM for rat EP2, IC50s = 
>3,200 nM for EP1, EP2, 





Sulprostone 14765 Ki = 0.35 nM, IC50 = 0.01 µM 





L-902,688 10007712 Ki = 0.38 nM, EC50 = 0.6 nM for 
EP4, >4,000-fold selective over 








10010410 IC50 = 2.5 nM for EP1, >400-fold 
selective over EP1, EP2, 







15016 IC50 = 16 nM for EP2 , >1000-
fold selective over EP1, EP3, 





L-798,106 11129 Ki = 0.3, 916, 5,000, >5,000 nM 
for EP3, EP4, EP1, EP2, 







19742 Ki = 11.7, >10,000, >10,000 nM 
for EP4, EP2, EP3, respectively 







2.5 Data processing and analysis  
All the electrophysiological patch clamp recordings were amplified using Multiclamp 700B 
(Axon CNS Molecular devices), low-pass filtered between 1-10 kHz, and digitized at 20 kHz 
using a Digidata 1550B (Axon Instruments Molecular devices Electrophysiology). The 
recordings were analyzed off-line using Clampfit 10.7 software (pClamp, Molecular 
devices). eIPSC amplitude was calculated by subtraction of each traces’ peak amplitude from 
the 1 second long pre-stimulation baseline. All data was normalized and presented as a 
percentage of the average baseline (-5 - 0 min, pre-drug application) in the 1-minute bins 
represented as a time-course plot. The effects were observed in the post-drug bin (5 - 10 min) 
after drug application reached maximum concentration and had time to act. The frequency 
and amplitude of eIPSCs, the paired-pulse ratio, and the coefficient of variation (CV) were 
analyzed and are presented in 1-minute bins. sIPSC events were detected, confirmed visually, 
and counted for frequency, with amplitude calculated similar to eIPSCs using MiniAnalysis 
software (Synaptosoft). Data are presented as many individual recordings or mean ± s.e.m. 
2.6 Statistical analysis  
All statistical analyses were performed in GraphPad Prism 7 (GraphPad Software Inc., CA, 
USA). Statistical significance was tested using one-way sample t-test in all experiments with 
normalized data; t-tests contrasted the post-drug bin (5 - 10 min) with the hypothetical mean 
of 100%. In cases while comparing absolute values, a paired parametric t-test was used to 
compare the wash time bin (5 - 10 min) with the baseline bin (-5 - 0 min). To analyze the 
correlation between two variables, linear regression analysis was applied. An R2 coefficient 
was calculated as a measure of fit and a t-test was performed comparing the slope of the 
regression line to 0. A probability value (p) of < 0.05 was considered as statistically 
significant. 
2.7 Synaptic properties assessed: Identifying pre- and post-
synaptic locus of effect 
The efficacy of synaptic transmission is generally determined by the following three 
independent variables: the probability of the neurotransmitter release (Pr), numbers of 




neurotransmitter release, whereas Q reflects the post-synaptic receptor function. Plastic 
changes of a synapse could affect any combinations of Pr, N and Q. During patch clamp 
electrophysiology, one can record the post-synaptic current (PSC) or voltage. While 
recording PSC, it is possible to use specific protocols to record synaptic properties that can 
be used to determine Pr, N and Q associated with synaptic plasticity as is summarized in 
Table 2-3 (Branco & Staras, 2009; Faber & Korn, 1991; Korn & Faber, 1991). These 
synaptic properties include: the paired-pulse ratio (PPR) and the CV of the eIPSCs as well as 
the frequency and amplitude of the sIPSCs. 
2.7.1 Paired-pulse ratio 
When recording eIPSCs, two pulses are delivered with an interstimulus interval of 50 ms, 
which evoked 2 separate eIPSCs. The PPR is the amplitude of the second eIPSC over the 
first eIPSC (PPR = 
P2
P1
). Synapses with high Pr tend to have PPR < 1, while low Pr synapses 
tend to have PPR > 1. If a type of plasticity alters the PPR, it indicates changes in Pr and pre-
synaptic locus of the plasticity mechanism. Paired-pulse depression (decreased PPR) 
generally indicate an increase in Pr, as high Pr uses up readily releasable vesicles during the 
first pulse so fewer vesicles are available for the second pulse. Conversely, paired-pulse 
facilitation (increased PPR) generally indicates a decrease in Pr, due to the combinations of 
less depletion of readily releasable vesicles by the first pulse and accumulation of Ca2+ in the 
pre-synaptic terminals by two consecutive pulses. When synaptic plasticity is due to the 
changes in the post-synaptic receptor functions, the amplitude of the first and second peaks 
should be affected equally, and thus PPR should remain stable. Importantly, a lack of change 
of PPR is not an indication of a post-synaptic mechanism, but rather a lack of indication of a 
pre-synaptic mechanism. Some post-synaptic mechanisms may affect PPR such as 
desensitization of post-synaptic receptors, but these have not been well studied (Blitz, Foster, 
& Regehr, 2004). Generally, PPR a measure fairly specific for pre-synaptic mechanisms 















 σ is the standard deviation, 
μ is the mean 
Each eIPSC is composed of a sum of many different contributions of individual vesicle 
releases and synapse firing. A variable synapse has high CV and thus low 
1
CV2
. One major 
contributor to stable (low CV) synapses is a large number of active pre-synaptic release sites 
(high N), as the average firing of a larger population is more consistent. By contrast, more 




 is a characteristic of the Pr and the N of the pre-synaptic neuron. If a treatment 
affects the pre-synaptic site of a synapse, altering its Pr or N, then the 
1
CV2
 should change 
(facilitation or depression). If 
1
CV2
 decreases, then the synapse is more variable, potentially 
due to fewer functional pre-synaptic release sites (decreased N). Or, if 
1
CV2
 decreases, it may 
be due to a decrease of Pr. By contrast, the post-synaptic receptor population do not create 





2.7.3 sIPSC Frequency 
The frequency of the sIPSC generally indicates the frequency of neurotransmitter release 
from the pre-synaptic terminals and is therefore determined by the combination of Pr and N. 
In addition, sIPSC frequency is influenced by the frequency of (spontaneous) action potential 
firing of the pre-synaptic neurons. Thus, changes in sIPSC frequency informs changes in Pr, 
N and/or pre-synaptic neurons’ action potential firing. Fewer synaptic partners (low N) or 




(frequency). By contrast, if the treatment causes an effect via post-synaptic receptors, then 
the sIPSC frequency remains unchanged. 
2.7.4 sIPSC Amplitude 
The average amplitude of sIPSCs is a characteristic of the Q, a major predictor of post-
synaptic neuron receptor modulation. Q refers to the population average of the post-synaptic 
response to the release of a single vesicle that contains neurotransmitter. Thus, in general, Q 
is modulated post-synaptically by changing the response to the released transmitter. sIPSC 
amplitude decreases may reflect a decrease in the responsiveness of the post-synaptic 
receptors to a vesicle release (decreased Q). By contrast, if the treatment causes an effect via 
pre-synaptic receptors, then the sIPSC amplitude remains unchanged. However, while Q is 
generally considered post-synaptic, some evidence towards pre-synaptic affects includes 
changes in the amount of neurotransmitter packaged, given that post-synaptic receptors are 




Table 2-3: Changes of synaptic properties that are associated with synaptic plasticity 
changes. 
Decreases in the probability of release (Pr), numbers of synapses (N), and quantal size (Q) 
are associated with changes in the paired pulse ratio (PPR), coefficient of variation (CV), 
spontaneous inhibitory post-synaptic current (sIPSC) amplitude and sIPSC frequency. Pr and 
n are associated with pre-synaptic loci of effects, while Q is associated with post-synaptic a 











Pre- ↓ Pr ↑ ↓ - ↓ 
Pre- ↓ n - ↓ - ↓ 







3.1 PGE2 depresses GABAergic synaptic transmission onto 
CRH neurons via a pre-synaptic mechanism 
Using rats, our former M.Sc. student recently showed that PGE2 suppresses GABAergic 
synaptic transmission onto PNCs in the PVN, a plausible mechanism for immune-induced 
activation of the HPA axis (Khazaeipool et al., 2018). My thesis is built on this finding – 
aiming to further examine the effects of prior psychological stress on this PGE2-induced 
GABA synapse plasticity. To this end, I first aimed to change our animal model from rat to 
mouse because of the availability of a CRH reporter mouse line (Cusulin et al., 2013). In rats, 
PNCs are identified based on their morphology and electrophysiological fingerprint (Figure 
1-5). While PNCs are operationally defined as putative CRH neurons, they also include non-
CRH neurons like TRH-, and GHIH-expressing neurons (Ceccatelli et al., 1989; Pammer et 
al., 1988; Stern, 2015). The transition to a mouse model was essential to accurately identify 
CRH neurons and reduce variability in the data due to the cellular heterogeneity. Therefore, 
the first aim of my thesis is to replicate the finding of the mechanism of PGE2 action from the 
rat model in the CRH reporter mouse model where CRH neurons can be visually identified in 
slice electrophysiology by the expression of TdTomato (Cusulin et al., 2013).  
Consistent with our rat study (Khazaeipool et al., 2018), we found that bath application of 
PGE2 (1 µM for 5 min) decreased the amplitude of eIPSCs (53.25 ± 11.01% of the baseline, 
p = 0.0022, n = 10) (Figure 3-1 A, B, C) recorded in CRH neurons in PVN slices prepared 
from naïve mice. Our rat study also reported that PGE2 achieves this depression of 
GABAergic transmission via a pre-synaptic mechanism as was evidenced by 1) an increase 
in the PPR, 2) decrease in the 
1
CV2
, 3) a decrease in the sIPSC frequency, and 4) no change in 
the sIPSC amplitude, according to Table 2-3. Consistent with this, the PGE2-induced 
depression of eIPSC amplitude in mice was accompanied by an increase in PPR (138.10 ± 
9.62% of baseline, p = 0.0033, n = 10) and a decrease in 
1
CV2
 (32.04 ± 8.53% of baseline, p < 




correlate with the change in PPR (R2 = 0.3866, p = 0.0549) and 
1
CV2
 (R2 = 0.1575, p = 0.2562) 
(Figure 3-1 D). Similar to our rat study, the analysis of sIPSCs revealed that PGE2 decreased 
the frequency of sIPSCs (61.41 ± 11.33% of baseline, p = 0.0078, n = 10) (Figure 3-1 E, G, 
H, I) but did not change the mean amplitude of the sIPSCs (96.58 ± 3.07% of baseline, p = 
0.2938, n = 10) (Figure 3-1 E, F, H, I). These changes in synaptic properties are consistent 
with the pre-synaptic mechanisms suggested in previous studies (Khazaeipool et al., 2018). 
Together, these data suggest that PGE2 depress GABAergic transmission onto PVN-CRH 
neurons in mice via a pre-synaptic mechanism, similar to what we have reported in PNCs in 










Figure 3-1:8 PGE2 depressed GABA transmission on CRH neurons in naïve mice.  
(A) An example of a typical eIPSC recording in a naïve mouse, comparing baseline (black) 
and after PGE2 (blue) application. (B) Individual time-course of eIPSC 1 amplitude. (C) 
Summary time-course of normalized eIPSC 1 amplitude, PPR, and 
1
CV2
. (D) Correlation plot 
of eIPSC (% baseline) with PPR (orange) or 
1
CV2
 (purple) after treatment with PGE2. The 
lines represent the linear best fit regression for PPR (orange) and 
1
CV2
 (purple). (E) An 
example of a typical sIPSC recording in a naïve mouse, comparing baseline (black) and after 
PGE2 (blue) application. (F) Individual time-course of sIPSC frequency and (G) sIPSC 
amplitude. (H) Summary time-course of normalized sIPSC frequency (orange) and amplitude 
(purple). (I) Correlation plot of eIPSC (% baseline) with sIPSC frequency (orange) or 
amplitude (purple) after treatment with PGE2. The lines represent the linear best fit 
regression for sIPSC frequency (orange) or amplitude (purple). For all graphs, the horizontal 





3.2 Acute restraint stress alters the PGE2 depression of 
GABAergic synaptic transmission onto CRH neurons 
Psychological stress alters the sensitivity of the HPA axis to inflammation in vivo (Johnson et 
al., 2002; Gadek-Michalska et al., 2005). My thesis asked whether prior exposure to 
psychological stress alters the actions of PGE2 on the GABAergic synapses onto PVN-CRH 
neurons. To test this, we challenged a mouse with a one hour restraint stress, a widely used 
psychological stress in rodents (Chu et al., 2016; Gadek-Michalska et al., 2005; Roper, 
Craighead, O’Carroll, & Lolait, 2010; Zimprich et al., 2014) and immediately after the end of 
restraint prepared acute brain slices for electrophysiological recordings. We found that 
restraint stress made the effects of PGE2 heterogeneous. That is, in brain slices from acutely 
stress mice, PGE2 depressed some GABA transmission on CRH neurons (42.90 ± 6.21% of 
baseline, p < 0.0001, n = 9 of 13) (Figure 3-2 A [i], B, C) but also potentiated GABA 
signaling other neurons (135.67 ± 12.60% of baseline, p = 0.0472, n = 4 of 13) (Figure 3-2 A 
[ii], B, C). The magnitude of depression after stress was similar to that of naïve animal PGE2 
application (42.90 ± 6.21% of baseline vs. 53.25 ± 11.01% of the baseline, p = 0.4388). 
I next analyzed changes in the PPR, 
1
CV2
, sIPSC frequency and amplitude to tease out the pre- 
and/or post-synaptic mechanisms of the synaptic changes. Since post-stress PGE2 caused two 
different responses – depression and potentiation – of the eIPSC, I assessed the synaptic 
properties of these recordings separately. Like in naïve conditions, the depression of eIPSC 
amplitude was accompanied by an increase in PPR (130.10 ± 9.47% of baseline, p = 0.0130, 
n = 9) and a decrease in 
1
CV2
 (34.35 ± 10.18% of baseline, p = 0.0002, n = 9) (Figure 3-2 C, 
D). Likewise, there was a trend of decrease in sIPSC frequency that did not reach statistical 
significance (61.33 ± 18.06% of the baseline, p = 0.0695, n = 8 [1 recording excluded: 
insufficient baseline sIPSC frequency (<0.5 Hz)]) (Figure 3-2 E [i], G, H, I), whereas there 
was no change in sIPSC amplitude (91.28 ± 4.25% of the baseline, p = 0.0792, n = 8) 
(Figure 3-2 E [i], F, H, I). These data suggest that PGE2-induced eIPSC depression in 
acutely stressed animals is likely pre-synaptic, like in naïve conditions. When PGE2 
potentiated the amplitude of eIPSCs, this potentiation was accompanied by a decrease in the 







(179.80 ± 27.19% of baseline, p = 0.0607, n = 4) (Figure 3-2 E [ii], G, H, I). Neither the 
frequency (93.47 ± 39.15% of the baseline, p = 0.8782, n = 4) nor the mean amplitude 
(103.90 ± 8.86% of the baseline, p = 0.7043, n = 4) (Figure 3-2 E [ii], F, H, I) of sIPSCs 
changed. Together, these data suggest that PGE2 potentiates eIPSC amplitude via an increase 









Figure 3-2:9 Acute restraint stress alters PGE2-induced effects on GABA transmission 
on CRH neurons. 
(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing 
baseline (black) and after PGE2 (red) application for a neuron that (i) depressed and (ii) 
potentiated. (B) Individual time-course of eIPSC 1 amplitude. (C) Summary time-course of 
normalized eIPSC 1 amplitude, PPR, and 
1
CV2
 for the population of neurons that depressed 




 (purple) after treatment with PGE2. The lines represent the linear best fit regression for 
PPR (orange) and 
1
CV2
 (purple) for the population of neurons that depressed (dark) and 
potentiated (light). (E) An example of a typical sIPSC recording in an acutely restrained 
mouse, comparing baseline (black) and after PGE2 (red) application for a neuron that (i) 
depressed and (ii) potentiated. (F) Individual time-course of sIPSC frequency and (g) sIPSC 
amplitude. (H) Summary time-course of normalized sIPSC frequency (orange) and amplitude 
(purple) for the population of neurons that depressed (dark) and potentiated (light). (I) 
Correlation plot of eIPSC (% baseline) with sIPSC frequency (orange) or amplitude (purple) 
after treatment with PGE2. The lines represent the linear best fit regression for sIPSC 
frequency (orange) or amplitude (purple) for the population of neurons that depressed (dark) 
and potentiated (light). For all graphs, the horizontal line represents the time and duration of 





3.3 Depression of GABAergic synaptic transmission onto CRH 
neurons is mediated by EP3  
Our data thus far demonstrated that prior exposure to a single restraint stress alters the effects 
of PGE2 on GABA synapses. Specifically, after restraint stress PGE2 potentiated some 
synapses/cells. Our previous rat study showed that the PGE2-mediated depression of GABA 
release is mediated by EP3 receptor subtype (Khazaeipool et al., 2018). These data lead us to 
hypothesize that restraint stress down-regulated EP3 receptor in some, but not, all synapses 
and that this down-regulation unmasked an opposing potentiation.  
In slices from naïve mice, bath application of EP3 agonist (sulprostone, 1 µM for 5 min) 
reduced the eIPSCs amplitude (55.81 ± 5.80% of baseline, p < 0.0001, n = 9) (Figure 3-3 A, 
B, C), which is similar in magnitude to that of PGE2 (vs. 53.25 ± 11.01% of the baseline, p = 
0.8568). This is again in line with our recent finding in rats regarding the roles of EP3 
receptors mediating PGE2-mediated depression of eIPSCs (Khazaeipool et al., 2018). The 
analysis of synaptic parameters found that EP3 agonist decreased 
1
CV2
 (47.58 ± 10.22% of 
baseline, p = 0.0009, n = 9). However, it did not change PPR (108.90 ± 8.56% of baseline, p 
= 0.3314, n = 9) (Figure 3-3 C, D). The lack of PPR change by EP3 agonist, by contrast to its 
robust increase by PGE2 (108.90 ± 8.56% of baseline, vs. 138.10 ± 9.62% of baseline, p = 
0.0382) suggests that it is the contribution of other EP receptors (EP1, EP2, and EP4) that 
increases PPR after the application of PGE2. EP3 agonist decreased the frequency (46.60 ± 
8.41% of baseline, p = 0.0002, n = 9) (Figure 3-3 E, G, H, I) without changing the mean 
amplitude (99.20 ± 9.94% of baseline, p = 0.9382, n = 9) of sIPSCs (Figure 3-3 E, F, H, I). 
Overall, the EP3-mediated depression of eIPSCs is accompanied by changes indicative of a 
decrease in the number of functional GABA synapses, which is consistent with pre-synaptic 
synaptic depression mechanism. The decrease in cAMP due to Gαi/o has previously been 
linked to decreasing neurotransmitter release (Atwood, Lovinger, & Mathur, 2014), 









Figure 3-3: EP3 decreases the amplitude of eIPSCs in naïve mice. 
(A) An example of a typical eIPSC recording in a naïve mouse, comparing baseline (black) 
and after EP3 agonist (blue) application. (B) Individual time-course of eIPSC 1 amplitude. 
(C) Summary time-course of normalized eIPSC 1 amplitude, PPR, and 
1
CV2
. (D) Correlation 
plot of eIPSC (% baseline) with PPR (orange) or 
1
CV2
 (purple) after treatment with EP3 




(E) An example of a typical sIPSC recording in a naïve mouse, comparing baseline (black) 
and after EP3 agonist (blue) application. (F) Individual time-course of sIPSC frequency and 
(G) sIPSC amplitude. (H) Summary time-course of normalized sIPSC frequency (orange) 
and amplitude (purple). (I) Correlation plot of eIPSC (% baseline) with sIPSC frequency 
(orange) or amplitude (purple) after treatment with EP3 agonist. The lines represent the linear 
best fit regression for sIPSC frequency (orange) or amplitude (purple). For all graphs, the 





3.4 Acute restraint stress does not alter the EP3-mediated 
depression of GABAergic synaptic transmission onto CRH 
neurons 
We next examined the effects of applying an EP3 agonist on slices from restraint stressed 
mice. Contrary to our hypothesis that restraint stress impairs the EP3 receptor-mediated 
GABA synapse depression, EP3 agonist decreased the amplitude of the eIPSCs in slices from 
restraint stressed mice (45.02 ± 6.99% of baseline, p = 0.0001, n = 8) (Figure 3-4 A, B, C) in 
the magnitude comparable to what we found in naïve slices EP3 application (45.02 ± 6.99% 
of baseline vs. 55.81 ± 5.80% of baseline, p = 0.2585). These data indicate that EP3-mediated 
depression is intact after acute stress. Similar to naïve mice, EP3 agonist applied to the 
acutely stressed mice slices decreased the 
1
CV2
 (43.81 ± 11.81% of baseline, p = 0.0021, n = 
8). EP3 application to stressed mice increased PPR (131.80 ± 13.03% of baseline, p = 0.0450, 
n = 8) (Figure 3-4 C, D), unlike in naïve slices (vs. 108.90 ± 8.56% of baseline, p = 0.0542), 
pointing to a possibility that stress can contribute to the increase in PPR. sIPSC analysis 
showed that EP3 agonist decreased frequency (64.23 ± 14.19% of baseline, p = 0.0398, n = 8) 
(Figure 3-4 E, G, H, I) but did not change amplitude (91.54 ± 6.40% of baseline, p = 0.2276, 
n = 8) (Figure 3-4 E, F, H, I). Overall, these data suggest that EP3 receptor continues, after 










Figure 3-4:10 Acute stress does not modulate EP3-mediated suppression of GABA release. 
(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing 
baseline (black) and after EP3 agonist (red) application. (B) Individual time-course of eIPSC 




Correlation plot of eIPSC (% baseline) with PPR (orange) or 
1
CV2
 (purple) after treatment with 




(purple). (E) An example of a typical sIPSC recording in an acutely restrained mouse, 
comparing baseline (black) and after EP3 agonist (red) application. (F) Individual time-course 
of sIPSC frequency and (G) sIPSC amplitude. (H) Summary time-course of normalized 
sIPSC frequency (orange) and amplitude (purple). (I) Correlation plot of eIPSC (% baseline) 
with sIPSC frequency (orange) or amplitude (purple) after treatment with EP3 agonist. The 
lines represent the linear best fit regression for sIPSC frequency (orange) or amplitude 
(purple). For all graphs, the horizontal line represents the time and duration of drug 





3.5 Blocking EP3 receptor removes the PGE2 suppression of 
GABA release onto CRH neurons in naïve mice 
Our next hypothesis was that restraint stress altered non-EP3 receptors that cause an opposing 
potentiation and overcome the EP3-mediated depression of GABA release. To test this, we 
applied PGE2 in the presence of an EP3 antagonist. In slices from naïve mice, PGE2 in the 
presence of EP3 antagonist (L-798, 106, 1 µM for recording duration) did not depress the 
eIPSC amplitude but rather resulted in a trend toward potentiation that did not reach 
statistical significance (112.50 ± 5.77% of baseline, p = 0.0590, n = 10) (Figure 3-5 A, B, 
C). EP3 antagonist fully blocks PGE2-induced depression of GABA (112.50 ± 5.77% of 
baseline vs. 53.25 ± 11.01% of the baseline, p = 0.0002). Consistent with the block of PGE2 




(109.20 ± 19.63% of baseline, p = 0.6515, n = 10) (Figure 3-5 C, D), sIPSC frequency 
(90.30 ± 26.15% of baseline, p = 0.7233, n = 7 [remainder of data still in analysis])) (Figure 
3-5 E, G, H, I) or sIPSC amplitude (112.90 ± 7.99% of baseline, p = 0.1567, n = 7 
[remainder of data still in analysis]) (Figure 3-5 E, F, H, I). These data further support that 











Figure 3-5:11 EP3 antagonist blocks suppression of eIPSCs in naïve mice. 
(A) An example of a typical eIPSC recording in a naïve mouse, comparing baseline EP3 
antagonist (black) and after PGE2 agonist (blue) application. (B) Individual time-course of 
eIPSC 1 amplitude. (C) Summary time-course of normalized eIPSC 1 amplitude, PPR, and 
1
CV2
. (D) Correlation plot of eIPSC (% baseline) with PPR (orange) or 
1
CV2
 (purple) after 
treatment with PGE2 during EP3 antagonist. The lines represent the linear best fit regression 
for PPR (orange) and 
1
CV2
 (purple). (E) An example of a typical sIPSC recording in a naïve 
mouse, comparing baseline EP3 antagonist (black) and after PGE2 agonist (blue) application. 
(F) Individual time-course of sIPSC frequency and (G) sIPSC amplitude. (H) Summary time-
course of normalized sIPSC frequency (orange) and amplitude (purple). (I) Correlation plot 
of eIPSC (% baseline) with sIPSC frequency (orange) or amplitude (purple) after treatment 
with PGE2 during EP3 antagonist. The lines represent the linear best fit regression for sIPSC 
frequency (orange) or amplitude (purple). For all graphs, the horizontal line represents the 





3.6 Acute restraint stress alters the non-EP3-mediated 
depression of GABAergic synaptic transmission onto CRH 
neurons 
We next repeated the experiment in slices from restraint stressed mice. We found that the 
presence of EP3 antagonist unmasked PGE2-mediated potentiation after restraint stress 
(114.50 ± 4.08% of baseline, p = 0.0075, n = 9) (Figure 3-6 A, B, C). However, the 
magnitude of the potentiation was not significantly larger than naïve (114.50 ± 4.08% of 
baseline vs. 112.50 ± 5.77% of baseline, p = 0.7843). PGE2 in the presence of EP3 antagonist 
decreased PPR (88.97 ± 4.37% of baseline, p = 0.0355, n = 9) (Figure 3-6 C, D). This 
suggests that the potentiation of eIPSC amplitude involves an increase in Pr and thus a pre-




(116.40 ± 23.55% of baseline, p = 0.5054, n = 9) (Figure 3-6 C, D) or sIPSC frequency 
(94.49 ± 14.33% of baseline, p = 0.7107, n = 9) (Figure 3-6 E, G, H, I). There was an 
increase of the sIPSC amplitude (115.80 ± 6.24% of baseline, p = 0.0355, n = 9) (Figure 3-6 
E, F, H, I), pointing to a possibility for post-synaptic mechanisms that is recruited by non-










Figure 3-6:12 Acute stress may modulate non-EP3-mediated suppression of GABA 
release. 
(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing 
baseline EP3 antagonist (black) and after PGE2 agonist (red) application. (B) Individual time-








after treatment with PGE2 during EP3 antagonist. The lines represent the linear best fit 
regression for PPR (orange) and 
1
CV2
 (purple). (E) An example of a typical sIPSC recording in 
an acutely restrained mouse, comparing baseline EP3 antagonist (black) and after PGE2 
agonist (red) application. (F) Individual time-course of sIPSC frequency and (G) sIPSC 
amplitude. (H) Summary time-course of normalized sIPSC frequency (orange) and amplitude 
(purple). (I) Correlation plot of eIPSC (% baseline) with sIPSC frequency (orange) or 
amplitude (purple) after treatment with PGE2 during EP3 antagonist. The lines represent the 
linear best fit regression for sIPSC frequency (orange) or amplitude (purple). For all graphs, 






3.7 EP2 and EP4 receptors potentiate GABA synapses onto 
PVN-CRH neurons but are not upregulated by stress 
We next sought for the mechanisms through which PGE2 potentiated GABA synapses. We 
hypothesized that EP2 and EP4 receptors were likely to mediate the potentiation as they are 
coupled to Gαs protein: Gαs signaling via cAMP signaling has been shown to stimulate 
neurotransmitter release from pre-synaptic terminals (Atwood, Lovinger, & Mathur, 2014). 
We predicted EP2 and/or EP4 receptor activation potentiates GABAergic synaptic 
transmission onto PVN-CRH neurons and that restraint stress augments this potentiation to 
overcome EP3-mediated depression in some synapses.  
Co-application of EP2 agonist (CP 544,326, 1 µM for 5 min) and EP4 agonist (L-902,688, 0.1 
µM for 5 min) significantly increased eIPSC amplitude (165.60 ± 17.35% of baseline, p = 
0.0194, n = 5) in naïve mice (Figure 3-7 A, B, C). EP2 and EP4 agonist application together 




 (261.30 ± 69.35% of baseline, p = 0.0806, n = 5) (Figure 3-5 C, D). Our 












Figure 3-7:13 EP2 and EP4 together mediate potentiation in naïve mice. 
(A) An example of a typical eIPSC recording in a naïve mouse, comparing baseline (black) 
and after EP2 and EP4 agonist (blue) application. (B) Individual time-course of eIPSC 1 




Correlation plot of eIPSC (% baseline) with PPR (orange) or 
1
CV2
 (purple) after treatment with 
EP2 and EP4 agonist. The lines represent the linear best fit regression for PPR (orange) and 
1
CV2
 (purple). For all graphs, the horizontal line represents the time and duration of drug 





We next asked if an acute restraint stress could enhance this potentiation mechanism, which 
aimed to explain the increased potentiation after PGE2. To this end, we repeated the 
experiment in slices from restraint stressed mice. Application of EP2 receptor agonist with 
EP4 agonist increased eIPSC amplitudes (136.70 ± 7.17% of baseline, p = 0.0037, n = 6) 
(Figure 3-8 A, B, C). However, contrary to my prediction, EP2 and EP4 receptor-mediated 
potentiation is not greater after stress than in naïve conditions (136.70 ± 7.17% of baseline 
vs. 165.60 ± 17.35% of baseline, p = 0.1330). During the potentiation of eIPSC amplitude, 




 (153.6 ± 26.34% of baseline, p = 0.0973, n = 6) (Figure 3-8 C, D). Overall, this 
data suggests that EP2 and EP4 mediate a potentiation that remains intact after stress with no 






Figure 3-8:14 EP2 and EP4 together do not mediate greater potentiation after acute 
restraint stress. 
(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing 
baseline (black) and after EP2 and EP4 agonist (red) application. (B) Individual time-course 
of eIPSC 1 amplitude. (C) Summary time-course of normalized eIPSC 1 amplitude, PPR, and 
1
CV2
. (D) Correlation plot of eIPSC (% baseline) with PPR (orange) or 
1
CV2
 (purple) after 




 (purple). For all graphs, the horizontal line represents the time and duration 





3.8 Blocking either EP2 or EP4 receptor abolishes PGE2-
mediated potentiation 
To further investigate the roles of EP2 and EP4 in GABA synapse transmission, we applied 
PGE2 in the presence of the antagonist for either EP2 or EP4 receptor. Because we observed 
PGE2-mediated potentiation only after restraint stress, these experiments were done in slices 
in restraint stressed mice. In the presence of EP2 receptor antagonist (PF-04418948, 1 µM for 
recording duration), PGE2 application potently depressed eIPSC amplitudes in all synapses 
(29.09 ± 4.21% of baseline, p < 0.0001, n = 6) (Figure 3-9 A, B, C), indicating that the 
PGE2-mediated potentiation requires EP2 receptor signaling. The depression of eIPSCs by 
PGE2 in the presence of EP2 receptor antagonist was accompanied by an increase in PPR 
(159.60 ± 14.77% of baseline, p = 0.0100, n = 6) and a decrease in 
1
CV2
 (14.42 ± 2.69% of 
baseline, p < 0.0001, n = 6) (Figure 3-9 C, D). 
Likewise, EP4 receptor antagonist (BCG-20-1531(HCl), 1 µM for recording duration) 
abolished PGE2-mediated potentiation, resulting in a homogeneous depression (33.89 ± 
7.00% of baseline, p = 0.0007, n = 5) (Figure 3-10 A, B, C). EP4 antagonist during PGE2 
application did not change the PPR (127.70 ± 20.46% of baseline, p = 0.2477, n = 5), but 
significantly decreased the 
1
CV2
 (29.11 ± 8.91% of baseline, p = 0.0013, n = 5) (Figure 3-10 
C, D). These data are in line with our earlier finding that EP3 receptor activation depressed 
eIPSC amplitude via the inhibition of GABA release from the pre-synaptic terminals. 
Additionally, that all potentiation is blocked by antagonizing just one of the EP2 and EP4 






Figure 3-9:15 Blocking EP2 receptor abolishes potentiation after acute restraint stress. 
(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing 
baseline EP2 antagonist (black) and after PGE2 agonist (red) application. (B) Individual time-








after treatment with PGE2 during EP2 antagonist. The lines represent the linear best fit 
regression for PPR (orange) and 
1
CV2
 (purple). For all graphs, the horizontal line represents 











Figure 3-10:16 Blocking EP4 receptor abolishes potentiation after acute restraint stress. 
(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing 
baseline EP4 antagonist (black) and after PGE2 agonist (red) application. (B) Individual time-








after treatment with PGE2 during EP4 antagonist. The lines represent the linear best fit 
regression for PPR (orange) and 
1
CV2
 (purple). For all graphs, the horizontal line represents 




3.9 Blocking EP1 receptor mimics acute psychosocial stress 
Potentiation could arise due to the activation of EP2 and EP4 receptors by PGE2 application 
post-stress, but this is not greater after stress as was observed with PGE2. One possibility is 
that EP2 and EP4-mediated potentiation is suppressed under naïve conditions and unmasked 
by stress. It is unlikely that EP3 receptor suppresses EP2 and EP4-potentiation since blocking 
EP3 did not unmask potentiation in naïve conditions. EP1 receptor is critical to the 
inflammation response, as is evident since its knockout impairs LPS-induced HPA axis 
activation (Matsuoka et al., 2003). Yet the effects of EP1 on the PVN-CRH neurons remains 
unknown.  
To examine potential roles of EP1 receptor in PGE2-mediated changes in GABAergic 
synaptic transmission, we pharmacologically blocked EP1 receptor during PGE2 application. 
In naïve animals, application of PGE2 in the presence of EP1 antagonist (GW 848687X, 1 µM 
for recording duration) resulted in a heterogeneous response: in some recordings we observed 
a depression of eIPSCs (49.51 ± 4.65% of baseline, p = 0.0004, n = 5 of 9) (Figure 3-11 A 
[i], B, C) and others potentiation (151.70 ± 21.17% of baseline, p = 0.0925, n = 4 of 9) 
(Figure 3-11 A [ii], B, C). These results somewhat mimic the effects of restraint stress which 
caused depression (49.51 ± 4.65% of baseline vs. 42.90 ± 6.21% of baseline, p = 0.4831) and 
potentiation (151.70 ± 21.17% of baseline vs. 135.67 ± 12.60% of baseline, p = 0.5767). The 
proportion of neurons that were depressed (n = 5 of 9 [56%] vs. n = 9 of 13 [69%]) and 
potentiated (n = 4 of 9 [44%] vs. n = 4 of 13 [31%]) is similar between EP1 antagonist naïve 
conditions compared to PGE2 stress conditions.  
In the naïve recordings that were depressed, there was a decrease in 
1
CV2
 (21.12 ± 7.92% of 
baseline, p = 0.0006, n = 5) with no change in PPR (104.00 ± 17.77% of baseline, p = 
0.8322, n = 5) (Figure 3-11 C, D). The lack of PPR change by PGE2 during EP1 antagonist, 
by contrast to its robust increase by PGE2 in naïve conditions (104.00 ± 17.77% of baseline, 
vs. 138.10 ± 9.62% of baseline, p = 0.0868) suggests that EP1 might be necessary to increase 
PPR. Regarding sIPSCs, in the recordings that were depressed, PGE2 in the presence of EP1 
antagonist decreased frequency (59.59 ± 4.77% of the baseline, p = 0.0011, n = 5) (Figure 3-




= 5) (Figure 3-11 E [i], F, H, I). This data is consistent with pre-synaptic EP3 receptor-
mediated depression of GABA release. In recordings that were potentiated, there was no 
change in PPR (109.90 ± 14.21% of baseline, p = 0.5352, n = 4), 
1
CV2
 (94.80 ± 32.67% of 
baseline, p = 0.8837, n = 4) (Figure 3-11 C, D), sIPSC frequency (98.56 ± 18.21% of the 
baseline, p = 0.9418, n = 4) (Figure 3-11 E [ii], G, H, I), or amplitude (104.50 ± 8.58% of 
the baseline, p = 0.6354, n = 4) (Figure 3-11 E [ii], F, H, I). The lack of change of any 
synaptic properties in PGE2-induced potentiated traces was unexpected, failing to indicate 
either pre- or post-synaptic locus, and we currently have no explanation for the results. 
However, considering the low sample number (n = 4), it is likely that increasing the sample 










Figure 3-11:17 Blocking EP1 receptor causes some neurons to potentiate GABA 
transmission on CRH neurons. 
(A) An example of a typical eIPSC recording in a naïve mouse, comparing baseline EP1 
antagonist (black) and after PGE2 (blue) application for a neuron that (i) depressed and (ii) 
potentiated. (B) Individual time-course of eIPSC 1 amplitude. (C) Summary time-course of 
normalized eIPSC 1 amplitude, PPR, and 
1
CV2
 for the population of neurons that depressed 




 (purple) after treatment with PGE2 during EP1 antagonist. The lines represent the 
linear best fit regression for PPR (orange) and 
1
CV2
 (purple) for the population of neurons that 
depressed (dark) and potentiated (light). (E) An example of a typical sIPSC recording in a 
naïve mouse, comparing baseline EP1 antagonist (black) and after PGE2 (blue) application 
for a neuron that (i) depressed and (ii) potentiated. (F) Individual time-course of sIPSC 
frequency and (G) sIPSC amplitude. (H) Summary time-course of normalized sIPSC 
frequency (orange) and amplitude (purple) for the population of neurons that depressed 
(dark) and potentiated (light). (I) Correlation plot of eIPSC (% baseline) with sIPSC 
frequency (orange) or amplitude (purple) after treatment with PGE2 during EP1 antagonist. 
The lines represent the linear best fit regression for sIPSC frequency (orange) or amplitude 
(purple) for the population of neurons that depressed (dark) and potentiated (light). For all 
graphs, the horizontal line represents the time and duration of drug application. Data are 





3.9.1 Blocking EP1 receptor after stress shifts balance of 
depression/potentiation to potentiation 
After restraint stress the application of PGE2 during EP1 antagonist resulted a mixture of 
eIPSCs that depress (74.36 ± 2.72% of baseline, p = 0.0672, n = 2 of 6) (Figure 3-12 A [i], 
B, C) and potentiate (146.50 ± 11.00% of baseline, p = 0.0242, n = 4 of 6) (Figure 3-12 A 
[ii], B, C). Interestingly, the balance of depression: potentiation after stress and EP1 
antagonist has further shifted towards potentiation after stress compared to EP1 antagonist 
applied in naïve conditions (n = 4 of 6 [67%] vs. n = 4 of 9 [44%]), in line with the 
suggestion that EP1 is downregulated by stress to release potentiation.  
In restraint stress recordings that depressed there was no change in PPR (140.90 ± 21.80% of 
baseline, p = 0.3120, n = 2) or 
1
CV2
 (64.44 ± 27.78% of baseline, p = 0.4222, n = 2) (Figure 3-
12 C, D). In traces that depress eIPSCs, the sIPSC analysis showed that PGE2 application 
with EP1 antagonist trends to decrease frequency (47.03 ± 8.80% of the baseline, p = 0.1048, 
n = 2) (Figure 3-12 E [i], G, H, I) with no change in amplitude (85.34 ± 4.87% of the 
baseline, p = 0.2040, n = 2) (Figure 3-12 E [i], F, H, I). Again, like in naïve conditions, the 
lack of synaptic properties changing suggests that it is other EP receptors (such as EP3) that 
alter synaptic properties during depression.  
In recordings of eIPSCs which potentiated there was no change in PPR (93.80 ± 11.93% of 
baseline, p = 0.63.91, n = 4) or 
1
CV2
 (123.10 ± 20.64% of baseline, p = 0.3448, n = 4) (Figure 
3-12 C, D). sIPSC analysis revealed does not change frequency (92.52 ± 28.97% of the 
baseline, p = 0.8130, n = 4) (Figure 3-12 E [i], G, H, I) or amplitude (110.10 ± 8.95% of the 
baseline, p = 0.3399, n = 4) (Figure 3-12 E [i], F, H, I). Similar to the case with the naïve 
slices, the lack of change of any synaptic properties in PGE2-induced potentiated traces was 
unexpected, and we currently have no explanation for the results. However, considering the 











Figure 3-12:18 Acute stress continues to shift EP1 receptor antagonization to potentiation 
of GABA transmission on CRH neurons. 
(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing 
baseline EP1 antagonist (black) and after PGE2 (red) application for a neuron that (i) 
depressed and (ii) potentiated. (B) Individual time-course of eIPSC 1 amplitude. (C) 
Summary time-course of normalized eIPSC 1 amplitude, PPR, and 
1
CV2
 for the population of 
neurons that depressed (dark) and potentiated (light). (D) Correlation plot of eIPSC (% 
baseline) with PPR (orange) or 
1
CV2
 (purple) after treatment with PGE2 during EP1 antagonist. 
The lines represent the linear best fit regression for PPR (orange) and 
1
CV2
 (purple) for the 
population of neurons that depressed (dark) and potentiated (light). (E) An example of a 
typical sIPSC recording in an acutely restrained mouse, comparing baseline EP1 antagonist 
(black) and after PGE2 (red) application for a neuron that (i) depressed and (ii) potentiated. 
(F) Individual time-course of sIPSC frequency and (G) sIPSC amplitude. (H) Summary time-
course of normalized sIPSC frequency (orange) and amplitude (purple) for the population of 
neurons that depressed (dark) and potentiated (light). (I) Correlation plot of eIPSC (% 
baseline) with sIPSC frequency (orange) or amplitude (purple) after treatment with PGE2 
during EP1 antagonist. The lines represent the linear best fit regression for sIPSC frequency 
(orange) or amplitude (purple) for the population of neurons that depressed (dark) and 
potentiated (light). For all graphs, the horizontal line represents the time and duration of drug 







This thesis examined synaptic mechanisms with relevance to the immune-induced activation 
of the HPA axis and their modulation by psychological stress. In Aim 1 and 2, we replicated 
key findings, which we had made previously in rats (Khazaeipool et al., 2018), in mice. 
Specifically, we showed that PGE2 suppressed the synaptic release of GABA onto PVN-
CRH neurons in slices from (normal) unstressed mice, and that this PGE2 effect was 
mediated by EP3 receptor (Aim 1). We also showed that an exposure to a psychological stress 
(prior to brain slice preparation) made the PGE2 effects on GABA release heterogeneous, 
causing a potentiation of GABA release in some, but not all, synapses (Aim 2). These results 
showed that the effects of PGE2 and their impairment by a psychological stressor (acute 
restraint) are preserved between rats and mice. This transition to a mouse model is necessary 
to take advantage of the CRH reporter line that can genetically identify CRH neurons in the 
PVN. Previously in rats, we recorded from electrophysiologically characterized, putative 
CRH neurons that include non-CRH neurons as well.  
After establishing the mouse model, we sought to tease out the mechanisms underlying the 
modulatory effects of psychological stress on the actions of PGE2 (Aim 3). Our data revealed 
function for the four different subtypes of EP receptors. First, EP3 receptor depressed the 
release of GABA, which is intact after psychological stress. Second, EP2 and EP4 receptors 
facilitated (conversely to EP3 receptor) the release of GABA onto PVN-CRH neurons, which 
also was not altered by psychological stress. Third, in the presence of an EP1 receptor 
antagonist in control (unstressed) slices, PGE2 caused heterogeneous changes in GABA 
release similar to what was observed after psychological stress. Taken together, our data 
suggested that EP1 receptor blocks EP2 and EP4 receptor-mediated potentiation in control 
slices and an exposure to psychological stress downregulates EP1 receptors, allowing the 
emergence of potentiation (Figure 4-1 A, B). Below, I will discuss the implications of these 




4.1 PGE2 suppresses GABAergic synaptic transmission on 
CRH neurons via pre-synaptic EP3 receptor in mice 
It is well documented that PGE2 mediates the activation of the HPA axis during systemic 
inflammation (Morimoto et al., 1989; Rivier & Vale, 1991). One potential mechanism 
through which PGE2 activates the HPA axis is the removal of tonic GABAergic inhibition 
from CRH neurons (disinhibition) (Bains et al., 2015; Hewitt et al., 2009; Sarkar, Wakefield, 
MacKenzie, Moss, & Maguire, 2011; Verkuyl, Hemby, & Joëls, 2004). For example, an 
earlier work by Ferri and Ferguson (2003), showed that application of IL-1β, a cytokine that 
stimulates the synthesis of PGE2 in the brain, or of PGE2 decreased the frequency of 
spontaneous GABAergic synaptic transmission to PVN-PNCs (Ferri & Ferguson, 2003). A 
recent study by our group found that PGE2 potently depresses both evoked and spontaneous 
release of GABA onto PVN-PNCs (Khazaeipool et al., 2018). Built on these findings, my 
thesis examined the effects of PGE2 on the GABAergic synapses onto CRH neurons in 
mouse using a CRH reporter line. In section 3.1, I showed that PGE2, in mouse, potently 
inhibits the release of GABA onto PVN-CRH neurons with a rapid (< 5 min) onset and a 
long-lasting effect (> 15 min), replicating a similar effect of PGE2 observed in rats.  
Matsuoka et al. had demonstrated that knocking out the EP3 receptor impaired the HPA axis 
activation in response to LPS administration (Matsuoka et al., 2003), suggesting EP3 receptor 
is essential in the inflammatory signaling path. Khazaeipool’s study specifically 
demonstrated that PGE2 action was mediated by EP3 receptor in mouse (Khazaeipool et al., 
2018). In section 3.3, I showed that EP3 agonist mimics the effects of PGE2, with a decrease 
in eIPSC amplitude of similar time-course, magnitude, and duration to that of PGE2, 
suggesting that EP3 receptor mediates the effects of PGE2. My data suggest pre-synaptic loci 
(Zucker & Regehr, 2002) for the actions of PGE2 and EP3 receptor. A pre-synaptic locus of 
action for EP3 receptor is consistent with histological studies that show that EP3 receptor 
proteins are expressed in the pre-synaptic axons terminating in the PVN (Nakamura et al., 
2000). Additionally, consistent with EP3 receptors operating in pre-synaptic GABA neurons, 
an in situ hybridization study has localized EP3 mRNA in the BNST, the DMH, and the 
POA, which are known to send GABAergic inputs to the PVN (Ek et al., 2000). My data 




al., 2005; Khazaeipool et al., 2018) and show that PGE2 actions are preserved between rats 
and mice. 
4.2 Restraint stress impairs PGE2-mediated suppression of 
GABA release 
Several studies have suggested that prior stress alters immune-induced activation of the HPA 
axis. For example, repeated restraint stress attenuated the rise of ACTH and CORT induced 
by LPS given one day after the last restraint stress in rats (Gadek-Michalska et al., 2005). On 
the other hand, another study found a sensitization of the LPS-induced ACTH and CORT 
response after a single inescapable tail shock (Johnson et al., 2002). These results pointed to 
the possibility that an exposure to one stressor can modulate – increase or decrease – 
subsequent HPA activation by a different stressor. How this type of HPA axis modulation 
occurs remains unclear. My thesis found that acute restraint stress reduced PGE2-mediated 
suppression of GABAergic synaptic transmission. I then examined the underlying 
mechanisms for this modulation.  
4.3 Mechanism for restraint stress altering PGE2 suppression 
of GABA 
4.3.1 EP3-mediated depression of GABA release is intact after 
stress 
In naïve mouse PVN, as discussed in section 4.1, PGE2 acts through EP3 receptor and 
decreases the release of GABA from the pre-synaptic terminal. EP3 receptor is coupled to 
Gαi/o, which decreases cAMP and commonly decreases neurotransmitter release (Atwood et 
al., 2014) from the pre-synaptic terminal. In the PVN, it has been reported that CB1 receptor, 
a Gαi/o coupled receptor, depresses GABA release and that repeated restraint stress 
downregulates CB1 thereby impairing the CB1-mediated inhibition of GABA release. Thus, 
we initially hypothesized that an acute restraint stress would down-regulate EP3 receptor and 
consequently would impair PGE2-mediated inhibition of GABA release. However, our 




EP3 receptor resulted in a reduction of GABA release in a virtually identical manner both in 
slices from normal and stressed mice. 
4.3.2 EP2 and EP4 receptors potentiate GABA release and are 
intact after stress 
In addition to the effects of EP3 receptor in depressing the release of GABA, we revealed that 
the activation of EP2 and EP4 causes potentiation of GABA release. Specifically, we found 
that co-application of specific EP2 and EP4 agonists potentiated eIPSC amplitude. The 
potentiation was accompanied by an increase of 
1
CV2
 with little changes in PPR, indicating 
that EP2/EP4 receptor activation increased the number of functional synapses releasing 
GABA. To our knowledge, this is the first demonstration that EP2 and EP4 receptors 
modulate synaptic functions in the PVN. Mechanistically, EP2 and EP4 receptors are coupled 
to Gαs and increase cAMP (opposite to Gαi/o-coupled EP3) (Narumiya et al., 1999), explaining 
how these receptors resulted in an increase of GABA release.  
Application of an antagonist for EP2 or EP4 abolished the PGE2-mediated potentiation after 
psychological stress. That all potentiation was removed by blocking either EP2 receptor or 
EP4 receptor suggests that the two might be co-dependent; thus, we conclude that it is 
essential to have both EP2 receptor and EP4 receptor for potentiation.  
In naive conditions, PGE2 application (i.e. activation of all EP1-4 receptors) results in the pre-
synaptic inhibition of GABA release, indicating that the EP3-mediated mechanism overrides 
the EP2- and EP4-mediated potentiation. It is only after an acute restraint stress that we found 
GABA synapse potentiation in some, but not all, synapses. Thus, we next hypothesized that 
restraint stress upregulates EP2 and EP4 receptors at some synapses, causing potentiation, 
even in the presence of EP3 receptor. However, agonist experiments found that restraint 




4.3.3 EP1 receptor gates EP2 and EP4 receptor-mediated 
potentiation 
In slices from naïve mice, we found that the blockade of EP1 receptor during PGE2 
application mimics the effects of acute restraint stress, resulting in a potentiation of a subset 
of GABA synapses. Since EP3-mediated depression predominated over EP2/EP4-mediated 
potentiation of naïve GABA synapses on PVN-CRH neurons, our current working hypothesis 
is that EP1 receptor inhibits EP2/EP4 receptors in naïve PVN. When EP1 receptor is 
pharmacologically blocked, it unmasks the competition between EP3 and EP2/EP4 receptors: 
some synapses become potentiated by EP2/EP4 receptor activity. Acute restraint stress 
downregulates the gating by EP1 receptors, unmasking the EP2/EP4 receptor-mediated 
potentiation. Consistent with acute restraint stress downregulating EP1 receptor, EP1 
antagonist application to slices from psychologically stressed mice did not further cause 
potentiation (i.e. occlusion). This proposed mechanism is consistent with the heterogenous 
response observed due to PGE2 application after restraint stress (where distinct populations 
potentiate and depresses): populations that depress lack EP2/EP4 receptor activity (necessary 
for potentiation) (Figure 4-1 C, D), while those that potentiate post-stress must contain at 
least EP2/EP4 and EP1 receptors (Figure 4-1 A, B). An earlier EP receptor KO mice study 
showed that EP1 receptor-, in addition to EP3 receptor-, deficient mice showed an impaired 
HPA axis response to systemic LPS administration (Matsuoka et al., 2003), suggesting that 
both EP1 and EP3 are necessary for PGE2-mediated activation of the HPA axis and aligned 
with this thesis’s results.  
In situ hybridization found EP1 receptor mRNA expression in the ventromedial preoptic 
nucleus, the median preoptic nucleus, and the PVN (Oka et al., 2000). On the other hand, 
major GABAergic inputs to the PVN originate from the anterior paraventricular nucleus, the 
anterior perifornical area, anterior hypothalamic, and dorsomedial hypothalamic nucleus 
(Cullinan et al., 2008; Roland & Sawchenko, 1993). Given that localization of EP1 receptor 
mRNA do not correspond with the major GABA inputs, currently there is no evidence to 
support the expression of EP1 receptor in the pre-synaptic terminals of the GABA synapses 




The neuronal mechanisms downstream of EP1 receptor activation remain largely unknown. 
EP1 receptor is a GPCR coupled with Gαq, as was briefly discussed in section 1.8. Gαq can 
stimulate PI3K for many downstream effects. Some of these downstream effects of PI3K are 
to cause PIP2 metabolism, leading to the formation of IP3 and DAG. IP3 increases 
intracellular Ca2+ level which can influence vesicle release, while DAG activates PKC for 
feedback regulation on EP1 and other EP receptors (Narumiya et al., 1999). Gαq signaling has 
also been shown to increase intracellular levels of Cl- through down-regulation of potassium 
chloride co-transporter (KCC)2 that typically establishes the Cl- gradient that makes GABA 
inhibitory. Rises of intracellular Cl- could lead to GABA signaling excitatory (Inoue & 
Bains, 2014). Since our data suggest that EP1 receptor is located post-synaptically, then to 
regulate pre-synaptic EP2 and EP4 receptor, Gq signaling must act retrogradely across the 
synapse. How EP1 receptor signaling inhibits EP2/EP4 requires future study.  
4.4 Potential purpose of an EP1 receptor-mediated mechanism 
EP1 receptor has a lower affinity of binding to PGE2 than any other EP receptor (Oka et al., 
2000), which may endow a wide dynamic range of HPA axis activity by PGE2, such that 
various concentrations of PGE2 can promote a range of responses, from mild to severe 
inflammation. The physiological roles of EP2 and EP4 signaling in the PVN remains 
unknown. EP2 and EP4 receptor KO mice showed an intact HPA axis activation after LPS 
challenge (Matsuoka et al., 2003). However, it remains to be examined if and how 
psychological stress alters the immune (LPS)-induced HPA axis activation in EP2/EP4 
receptor deficient mice. Beyond the HPA axis, EP4 receptor in the PVN has been implicated 
in anorexic response to inflammation (Ohinata, Suetsugu, Fujiwara, & Yoshikawa, 2006). 
4.5 Limitations and future directions 
This M.Sc. thesis demonstrates a plausible mechanism for acute psychological stress altering 
the GABA synaptic transmission on PVN-CRH neurons with relevance to the HPA axis 
activation (Figure 4-1 A, B). My data pointed to a potential model that EP1 receptor prevents 
the potentiation of GABA release by EP2 and EP4 receptors, thus indirectly contributing to 
EP3-mediated inhibition of GABA release. Along this line, we speculate that acute stress 




questions need to be tested to prove our working model. I will briefly explore types of 
experiments that need to be done in the future as well as alternative explanations to our 
current working hypothesis.  
4.5.1 Actions of EP1 
As a next step to test our working model, we should co-apply agonists for EP1, EP2 and EP4. 
If our model is correct, EP1 agonist will block the potentiation caused by EP2/EP4 agonists. 
Further studies might assess if EP1 receptor is altered by stress.  
This action of EP1 appears to be due to the post-synaptic actions of EP1 receptor, by contrast 
to the pre-synaptic effects of other EP receptors on GABA synapse transmission. The 
mechanism of post-synaptic action of EP1 receptor leading to the potentiation of eIPSCs 
remains unknown. However, one potential mechanism is that EP1 receptor activation alters 
Cl- homeostasis in the post-synaptic neuron. GABAA receptors are ligand-gated ion channels, 
which selectively conduct Cl- down their electrochemical gradient. In adult neurons, low 
intracellular Cl- causes Cl- influx through GABAA receptors at resting membrane potential 
(reversal potential = -70 mV), which causes hyperpolarization of the post-synaptic membrane 
(Olsen & DeLorey, 1999; Wu & Sun, 2015). Low intracellular Cl- is primarily achieved by 
the active extrusion of Cl- by KCC2 (Farrant & Kaila, 2007). Gq-coupled receptors have been 
shown to increase intracellular levels of Cl- through down-regulation of KCC2, which alters 
the Cl- gradient such that GABAA receptor signaling is less inhibitory or even excitatory 
(Inoue & Bains, 2014; Nabekura et al., 2002; Pathak et al., 2007). If EP1 receptor 
downregulates KCC2 post-synaptically, this would potentiate the eIPSC amplitude in our 
experimental conditions that record IPSCs by holding the post-synaptic neurons at -80 mV. 
To probe whether PGE2, via EP1, downregulates KCC2 to increase the intracellular Cl
- levels 
in PVN-CRH neurons, future experiments may measure if there is an alteration of the 
GABAA receptor reversal potential using patch-clamp electrophysiology.  
4.5.2 Psychological stress may alter EP3 receptor functions 
While our results showed no effects of acute psychological stress on EP3 receptor-mediated 




experiment was done with only one concentration of EP3 receptor agonist. It is possible that 
the dose we used (1 µM) saturated the effects of EP3 receptor and masked potential effects of 
psychological stress altering EP3 receptor functions. In line with this, EP3 receptor has a 
greater affinity for PGE2 than the other EP receptors (Coleman et al., 1994; Oka et al., 2000). 
Conducting a dose-response curve for EP3 agonist before and after an acute stress will clarify 
if stress modulates EP3-mediated depression.  
4.5.3 The origins of EP3-expressing GABAergic inputs on CRH 
neurons 
Our data replicate previous findings that pre-synaptic EP3 receptors suppress the release of 
GABA from GABAergic neurons projecting to the PVN. It is apparent both in our data in 
mice and rats (Khazaeipool et al., 2018) that there is heterogeneity in the response to PGE2. 
The origins of GABA inputs to PVN include: anterior hypothalamus (AH), DMH and the 
anterior perifornical area (part of the BNST) (Roland & Sawchenko, 1993). Each of these 
different inputs has different quantities of EP3 receptor, with the densest concentration being 
the DMH and the least in the BNST (Ek et al., 2000; Nakamura et al., 2000). These different 
GABA projections to the PVN containing different amounts of EP3 receptor may contribute 
relatively differently to the PGE2-mediated depression. Injection of a virus for expression of 
light-activated channelrhodospin 2 (optogenetics) into each of the nuclei of interest would 
allow for an input-specific recording and examination of the sensitivity to PGE2 and EP 
receptor agonists. This would discriminate the different contributions of each GABA input 
and potentially explain the intra-treatment heterogeneity.  
4.5.4 PGE2 actions beyond GABA synapses 
It is important to acknowledge that while I have suggested a mechanism affecting 
GABAergic synaptic transmission, it is likely that non-GABAergic mechanisms are acting in 
parallel in vivo. For example, the blockade of COX-1 and COX-2 for the synthesis of PGs 
decreases NA-induced activation of the HPA axis, indicating that PGE2 acts downstream of 
NAergic signaling (Bugajski, 1996). Conversely, it has been shown that a COX inhibitor, 




1998), indicating that PGE2 modulates the release of NA. Future research is necessary to 
investigate the actions of PGE2 besides GABA synapses.  
4.6 Significance 
One aspect of the immune response to inflammation involves the production of PGE2, which 
in turn activates the HPA axis (Narumiya & Furuyashiki, 2011). This immune-induced 
activation of the HPA axis can be modulated by prior psychological stress (Gadek-Michalska 
et al., 2005; Johnson et al., 2002). My research demonstrates a potential synaptic mechanism 
for the stress-modulation of immune-induced HPA axis response.  
Inflammation is one of our bodies defense mechanism against invading pathogens and 
injuries. Most presentations to primary care involve stress and many diseases feature 
inflammatory symptoms (Gluckman, Low, Buklijas, Hanson, & Beedle, 2011). GCs, as 
potent immunosuppressants, produced by the HPA axis acts for effective resolution of 
inflammation (Ruzek et al., 1999; Sapolsky et al., 2000). This negative feedback control of 
inflammation is important to prevent overactive immune response (Silverman, Pearce, Biron, 
& Miller, 2005). It is thus critical to understand how the brain, through the HPA axis, 
regulates inflammation. Dysregulation of the HPA axis and thus of GC production is 
implicated in abnormal and maladaptive inflammatory responses in diseases like sepsis 
(Kotas & Medzhitov, 2015) and arthritis (Angus & Wax, 2001; Schroeder et al., 2001). 
Advancing our understanding of the regulation of the immune-induced HPA axis and how it 
is susceptible to stress will inform us of potential mechanisms for the dysregulation of the 
HPA axis. Our findings on the synaptic mechanisms for HPA axis activation and how they 
may be impacted by a history of stress shed a light on the mechanisms that may be altered in 






Figure 4-1:19 Schematic diagram of the proposed synaptic mechanism of inflammation-
induced activation of the HPA axis and its change after acute restraint stress.  
In synapses that potentiate after stress, (A) in naïve conditions, PGE2 application causes 
depression of GABA synaptic transmission on CRH neurons as EP1 receptor blocks EP2 and 
EP4 receptor allowing pre-synaptic EP3 receptor to predominate; (B) in acute restraint stress 
conditions, PGE2 application causes potentiation of GABA synaptic transmission on CRH 
neurons as post-synaptic EP1 receptor is downregulated, allowing pre-synaptic EP2 and EP4 
receptor potentiation to predominate. In synapses that depress after stress, PGE2 application 
causes depression of GABA synaptic transmission on CRH neurons as via EP3 receptor (C) 
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